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Glossary of abbreviations and terms used. 
Phe (phenylalanine): An essential amino acid that patients with PKU are unable to 
metabolise normally. 
PKU (Phenylketonuria): An autosomal recessive, inborn error of metabolism affecting the 
hepatic enzyme PAH that causes phenylalanine (from diet or catabolism) to accumulate to 
toxic levels, causing neurocognitive defects. 
PAH (Phenylalanine Hydroxylase): Hepatic enzyme, the functioning of which is impaired in 
PKU due to mutations in the pair of alleles coding for it. This causes Phe to accumulate and 
makes Tyrosine essential as PAH ordinarily converts phe to it. 
BH4 (biopterin): co-factor required for PAH function. Mutations affecting enzymes involved 
in biosynthesis and regeneration impair PAH and cause Phe accumulation resembling PKU, 
but BH4 defects require differential treatment. Synthetic BH4 (Sapropterin) is a novel, oral 
treatment for PKU which improves PAH function in some cases, but only  subset of less 
severe cases (with some residual PAH functioning). 
Plasma phe: used to describe phe levels in blood, which are elevated in PKU and closely 
predict the extent of neurocognitive impairments. PKU is detected through elevations in 
plasma phe and treatment aims to control phe to avoid symptoms. 
Control: the objective of treatment is to ‘control’ phe. Treatment guidelines recommend 
maintaining phe within ranges associated with neurocognitive outcomes most similar to 
healthy controls. 
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Glossary of abbreviations and terms used (continued). 
Neurocognitive defects: deficits in (for example) intelligence, executive functions (e.g. 
reaction times) and movement disorders which are severe enough to necessitate lifelong 
institutionalisation in untreated PKU. However outcomes are often below-normal even in 
early-treated patients. This partly explains interest in novel treatments. 
Dietary treatment: Is initiated at birth to control plasma phe by restricting phe intake, 
which involves restricting most protein-containing foods, even staples. Phe-free protein 
substitutes (formula) are thus also needed to meet protein requirements. 
Early treated:  Patients treated within 3 months of birth. This is crucial as the developing 
CNS is particularly vulnerable to elevated phe and defects are worse if PKU is ‘late-treated’ 
(from 3 months to 7 years) and severely disabling if ‘untreated’ (until after 7 years). For the 
same reason, control targets are stricter (and tolerance lower) in children (until ~12-18 
years of age depending on the guideline used). 
Formula: phe-free protein substitutes. These are unpopular due to their poor taste, social 
acceptability and inconvenience which likely explain many patients struggling to comply 
with treatment. They are improving however, as flavoured, ready-to-drink pouches are now 
available whilst powdered versions requiring weighing and mixing were once the norm. 
Compliance with therapeutic diets: involves consuming sufficient formula, distributing it 
over 3-4 meals and eating the correct amounts of dietary protein and energy. Non-
compliance alters control by increasing phe intake or affecting the balance of anabolism 
(which lowers phe by incorporating it into tissues) and catabolism (which does the 
opposite). 
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Tolerance: Amount of dietary phe a patient can consume without losing control. Influenced 
by severity I.E. the extent to which PAH functions, which is determined by the mutation pair 
inherited. However not all are characterised and tolerance is not always predictable from 
genetic tests. Tolerance is worked out in practice by monitoring control and adjusting diet. 
Exchanges: System used to communicate tolerance to patients in food terms. Patients are 
assigned a number of exchanges of protein per day depending on tolerance and 
documentation lists how many exchanges foods contain. One exchange assumes 50mg phe 
per g protein which is a slight simplification. 
Guthrie Assay: The landmark, semi-quantitative method used to detect PKU at birth, 
allowing immediate treatment. Now superseded by more reliable methods such as tandem 
mass spectrometry of dried blood spots (DBS). 
Glycomacropeptide (GMP): The only naturally Phe-free intact protein. Used to manufacture 
medical foods forming novel alternatives to formula. These have several theoretical 
advantages over formula, particularly their acceptability. However, commercially viable 
purification processes are imperfect leaving GMP contaminated with some residual phe, 
raising concerns around its effect on control.  
LNAA (Large Neutral Amino Acids): A group of amino acids including phe which are 
absorbed from the gastrointestinal tract and cross the blood brain barrier via a shared 
transporter (L-type). LNAA treatment appears to reduce Plasma phe by competitively 
inhibiting phe uptake. GMP is naturally high in two LNAA (Thr & Ile) but requires 
supplementation with others (Arg, His, Leu, Trp, Tyr) to form a complete amino acid source. 
The degree of supplementation may thus influence GMPs impact on control
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0.0: Abstract. 
Conventional treatment for phenylketonuria restricts dietary phenylalanine to ‘control’ 
plasma phenylalanine concentrations. Its widespread adoption has largely eradicated the 
severe neurocognitive defects that previously characterised phenylketonuria. However, 
interest in alternative treatments continues as deficits in intelligence and other health 
outcomes remain problematic, conventional treatment has limitations and adherence 
proves difficult. Glycomacropeptide-based foods (GMP) are a novel treatment that may 
improve the satiety and acceptability of dietary treatment and address suboptimal health 
outcomes. However, glycomacropeptide contains some phenylalanine, raising safety 
concerns regarding its effect on plasma phenylalanine in adults and particularly children 
who tolerate less phenylalanine. This narrative review attempted to resolve these concerns. 
Its findings suggest adults and children can maintain control on GMP but individualised 
titrations, adjusting the amount of GMP consumed whilst monitoring plasma phenylalanine, 
are necessary in children. Equivalent control is a supportive finding given GMPs many 
advantages but this must be viewed cautiously as only seven studies were located, 
predominantly employing bias-prone, heterogeneous designs. GMPs effect upon control 
thus requires clarification via a systematic review using evidence-based, transparent 
methods to synthesize the entire evidence base and consider the impact of design quality, 
bias and heterogeneity upon results. 
1.0: Introduction. 
This narrative review evaluates the utility and safety of glycomacropeptide, a novel 
treatment for phenylketonuria. It first establishes phenylketonuria’s metabolic basis and 
how plasma phenylalanine concentrations, which predict the extent of neurocognitive 
symptoms, form the central marker in its study and treatment. It then describes the 
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severely disabling neurocognitive impairments that characterised phenylketonuria before 
treatment was discovered. Dietary treatment is next outlined. This restricts phenylalanine 
intake to control plasma phenylalanine concentrations (henceforth: plasma phe) and its 
widespread adoption has largely eradicated the life-changing disabilities that were 
previously commonplace. Despite such improvements, it is argued that intelligence and 
other health outcomes often remain below-normal, that treatment is burdensome and 
difficult to adhere to and that both factors explain continuing interest in novel treatments. 
Glycomacropeptide, one such treatment, is next evaluated. It is concluded that 
glycomacropeptide has the potential to improve the acceptability of therapeutic diets and 
ameliorate other suboptimal health outcomes, despite a lack of longer-term outcome data. 
However, glycomacropeptide contains phenylalanine, raising safety concerns regarding its 
impact on plasma phenylalanine control and neurocognitive outcomes. The reviews findings 
suggest maintenance of plasma phenylalanine is possible in adults and in children, provided 
individualised adjustments are performed in children but this conclusion is tentative as 
included studies predominantly employed bias-prone, heterogeneous designs. Resultantly, 
the review recommends that GMPs effect upon control is clarified using systematic methods 
that synthesize the entire evidence base and consider the impact of bias and heterogeneity 
upon results. 
2.0: Metabolic basis of Phenylketonuria. 
Phenylketonuria (PKU) is an autosomal recessive, inborn error of metabolism (IEM) that 
impairs functionality of the hepatic enzyme Phenylalanine Hydroxylase (PAH). PAH 
physiologically hydroxylates the essential amino acid (AA) phenylalanine, from dietary 
protein or tissue catabolism, to tyrosine (figure 1, left) (Williams, Mamotte, & Burnett, 
2008). Tyrosine is used biosynthetically or oxidised (Blau, van Spronsen & Levy, 2010) and 
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excess phenylalanine is excreted via tyrosine oxidation so its suppression (by decreased PAH 
activity) in Phenylketonuria causes phenylalanine accumulation in blood (HPA) and tissues 
(Blau et al., 2010; Williams et al., 2011).  
Figure 1. Suppression of the hydroxylation and excretion of Phe in PKU (left) and 
dependence of PAH on BH4 synthesis and regeneration (right). 
 
CNS = central nervous system. GTP = guanosine triphosphate. NADH = Nicotinamide adenine dinucleotide. 
Adapted from Blau et al., (2010). 
 
 Tetrahydrobiopterin (BH4) is a co-factor required by PAH. Mutations affecting enzymes 
involved in BH4 synthesis and regeneration (figure 1, right) can limit PAH activity, causing 
HPA resembling PKU (Longo, 2009). However BH4 has other roles (e.g. neurotransmitter 
synthesis) so BH4 defects require differential diagnosis and treatment (Blau, Hennermann, 
Langenbeck & Lichter-Konecki, 2011) and are henceforth excluded from the term PKU.   
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2.1: Pathophysiology of PKU and importance of plasma phe. 
How phe accumulation causes the neurocognitive symptoms that explain most morbidity in 
PKU (section 1.2) remains unclear. A detailed review of hypothetical mechanisms, which are 
not mutually exclusive, is unfeasible (see de Groot, Hoeksma, Blau, Reijngoud & van 
Spronsen, 2010; Blau et al., 2010) but these are summarised in figure 2 and two points 
noted. 
Figure 2: Mechanisms potentially linking Phe accumulation to neurocognitive symptoms.
 
 Tyr = Tyrosine.  BBB = Blood-Brain Barrier. LNAA = Large Neutral Amino Acids. LAT1 = LNAA type 1 transporter. 
HMG-CoA Reductase = Hydroxy-methyl-glutaryl-coenzyme-A reductase. PK = Pyruvate Kinase. Adapted from 
van Spronsen et al., (2017).  
Firstly, two disturbances (secondary to HPA) initiate every mechanism: elevated cerebral 
phe concetrations and decreased cerebral LNAA concentrations. Both occur as phe and 
other LNAA cross the BBB via the LAT-1 counter-transporter and HPA favours Phe uptake, 
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which competitively inhibits LNAA uptake and promotes LNAA counter-efflux (Pietz et al., 
1999; de Groot et al., 2010). Most importantly, the only factor implicated in every 
mechanism, routinely measurable (van Spronsen et al., 2017) and robustly predictive of 
neurocognitive outcomes is plasma phe as the extent and duration of elevations predict the 
severity of neurocognitive defects (Waisbren et al., 2007; Fonnesbeck, McPheeters, 
Krishnaswami, Lindegren & Reimschisel, 2012). Therefore, whatever pathological 
mechanism(s) plasma phe concentration forms a surrogate for, it is the central marker in 
the study and treatment of PKU. Elevations are used to diagnose PKU and treatment 
essentially maintains concentrations linked to favourable neurocognitive outcomes in the 
literature (van Wegberg et al., 2017).  
2.2: PKU is rare but causes severe disability if untreated. 
Compared to diseases considered major burdens to healthcare like diabetes PKU is rare. 
Table 1. Prevalence of PKU in UK with international comparisons 
Disease and 
Population 
Estimated 
Prevalence 
Possible explanation Source of  estimate 
Diabetes in England 
(over 16s only) 
1 in 11.6 -- Public Health England 
 (2016) 
PKU in Europe 1 in 10,000 --  Loeber et al., (2001)  
PKU in Turkey 
(incidence) 
1 in 4000  Consanguineous 
marriage  
Williams et al., (2008) 
PKU in Ireland 1 in 6200 Historically small & 
isolated gene pool  
Loeber et al., (2001) 
PKU in Scotland 1 in 7802 As above Loeber et al., (2001) 
PKU in Caucasians 
living in England 
1 in 10,000 -- Hardelid et al., (2008) 
 
PKU in Wales 1 in 10,700 -- Loeber et al., (2001) 
PKU in South Asians  
living in England 
1 in 33,000 Founder effects and/ or 
genetic drift 
Hardelid et al., (2008) 
PKU in Sub-Saharan 
Africans in England 
1 in 100,000 As above Hardelid et al., (2008) 
Finland (incidence) 1 in 200,000  As above  Williams et al., (2008)  
BH4 Defects <2% of PAH cases   Longo (2009)  
Adapted from essay previously submitted. 
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Untreated PKU is nevertheless associated with severe disability. Case reviews and surveys 
pre-dating the proliferation of treatment (Jervis, 1937; Paine, 1957) or involving patients 
born before it (Murphy et al., 2008; Mazur et al., 2011) describe severe intellectual 
impairments in most patients: ~70% attain IQs under 20 versus 1990 norms of ~110 (Smith, 
Beasley & Ades, 1990) and lifelong, 24-hour care is usually necessary. 
3.0: Treatment from birth and strict control in childhood are essential. 
Dietary treatment restricts phe intake to maintain plasma phe within ranges linked to 
neurocognitive outcomes (particularly intelligence and executive functions) closest to 
healthy controls in studies, particularly large syntheses (Waisbren et al., 2007; Fonnesbeck 
et al., 2012; Albrecht, Garbade & Burgard, 2009). This provides sufficient phe for growth and 
protein turnover but avoids accumulation. Treatment was discovered in 1954 (Bickel, 
Gerrard & Hickmans, 1954; Bickel, 1996). Those initially treated enjoyed marked intelligence 
improvements over untreated norms (MRC, 1963) but the inability to reliably diagnose PKU 
in newborns delayed treatment (Guthrie & Susi, 1963) despite the belief that immediate 
treatment would protect the rapidly developing (and theoretically more sensitive) CNS from 
phe and further improve outcomes (MRC, 1963; Guthrie & Susi, 1963; Koch & de la Cruz, 
1999). The Guthrie test was later developed (Guthrie & Susi, 1963) permitting screening and 
treatment at birth which rolled out across the USA and UK from ~1964 - 1971 (Koch & de la 
Cruz, 1999; Smith et al., 1990). Nationwide prospective studies during the rollout noted 
stratified associations between the rapidity of treatment initiation, IQ and school 
performance in ages 4-12, confirming the importance of early treatment (Smith et al., 1990; 
Beasley et al., 1994; Azen et al., 1991; Azen, Koch, Friedman, Wenz & Fishler, 1996). On this 
(observational) basis, newborn screening and early treatment are universally recommended 
and practiced in most developed nations, though policies vary (table 2). 
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Table 2 : Screening policies, diagnostic thresholds and recommended control ranges 
Treatment  
Guideline or policy 
(and source) 
Recommendations for 
screening and 
treatment initiation at 
birth. 
Threshold used to 
diagnose PKU at birth 
(untreated plasma phe 
in µmol/ L) 
Recommended 
plasma  
phe ranges in 
early life µmol/L 
Recommended  
plasma phe 
ranges in later life  
(µmol/L) 
Notes 
ESPKU European 
Guidelines 
(van Wegberg, 2017) 
Screen by day 3. 
Treat by day 10. 
>360 µmol/ L 120 – 360 
Until age 12 
120 – 600  
12 onwards (lifelong) 
Extent to which guidelines will be implemented 
in each European state is unclear. 
National Institutes of 
Health 
USA guidelines 
(NIH CDP, 2001) 
Universal screening 
since ~1963-70. 
Screen ASAP. 
Treat by day 7-10. 
>360 µmol/ L 120 – 360 
Until age 12 
120 – 900 
12 onwards (lifelong)  
Implementation varies by state/ clinic. 
MRC UK Guidelines 
(Smith et al, 1993) 
Universal screening 
since ~1971. 
Screen by day 5. 
Treat by day 20. 
>400 µmol/ L  120 – 360 
Until age 6 
120 – 700 
16 onwards 
(lifelong) 
Likely to be replaced by more recent ESPKU 
guidelines. 
120 – 480 
Ages 6 - 16 
German Guidelines 
(Burgard et al., 1999) 
Universal screening is 
standard. 
Screen and treat as 
soon as possible. 
>600 µmol/ L  40 – 240 
Until age 10 
40 – 1200 
15 onwards  
(lifelong) 
Ditto. 
40 – 900 
Ages 10 – 15 
Local policy in Paris, 
France  
(Abadie, 2000; Burgard et 
al., 1999) 
No national guideline. 
Universal screening 
since 1979 
Screen ASAP. 
Treat by day 14 
(median) 
>600 µmol/ L 120 – 420 
Until age 10 
 
<1200 – 1500 
After 10 years 
(Without formula) 
French policies are unusually relaxed due to 
cultural attitudes to food and disability. They 
previously advised discontinuation of formula at 
age 5 (see Rey, Abadie, Plainguet & Rey 1996).  
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In addition to rapid initiation of treatment, guidelines universally recommend stricter 
control (of plasma phe) in childhood (upto ages 10-12). This likewise minimises the 
developing CNS’ exposure to phe and has compelling evidential support. Prospective trials 
noted severe intellectual impairments following treatment discontinuation/ relaxation 
before ages five (Cabalska et al., 1977) and seven (Azen et al., 1996) but suffered 
compliance and randomisation problems as subjects aged, limiting their utility (Poustie & 
Wildgoose, 2010). However, nationwide prospective cohort studies correlating long-term 
control data with neurocognitive outcomes (Azen et al., 1991; Smith, Beasley & Ades, 1991) 
and meta-analyses combining these and other observational data with shorter trials 
(Waisbren et al., 2007; Fonnesbeck et al., 2012; Albrecht et al., 2009) confirmed that strict 
control until age ~12 are essential to prevent severe neurocognitive defects resembling 
those seen in untreated PKU. 
3.1: Lifelong treatment is universally recommended.  
Whilst guidelines permit relaxation of control in adolescence and adulthood, all 
recommended lifelong treatment (table 2) as subtle defects occur following cessation. 
Indeed, meta-analyses suggest control still influences intelligence (Waisbren et al., 2007; 
Fonnesbeck et al., 2012) and executive functions (Albrecht et al., 2009) from ages 12-18 
though the relationships weaken, suggesting control becomes less important. The 
importance of treatment after age 18 is less clear as lifelong trials are impractical and the 
retrospective designs most practicable cannot isolate defects from those attributable to 
control during earlier life (van Wegburg et al., 2017). However, data support lifelong 
continuation. Trials link even short-term treatment cessation in adulthood to mood and 
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cognitive defects (ten Hoedt et al., 2011) that improve if treatment recommences (Schmidt, 
Burgard & Rupp., 1996). Whilst their significance is unclear, white matter abnormalities also 
co-vary with concurrent plasma phe concentrations in adulthood (Anderson & Leuzzi, 2010) 
and reverse upon treatment recommencement (Cleary et al., 1995). Another rationale for 
lifelong treatment is uncertainty, as the first recipients of treatment are only ~60 years old. 
4.0: Suboptimal control and health remain common despite near-universal treatment. 
Treatment from birth is now universally recommended in most developed nations (Therrell 
et al., 2015; Hagedorn, van Berkel, Hammerschmidt, Lhotáková & Saludes, 2013) and 
considered successful (Blau et al., 2010; NIH CDP 2001; van Wegburg et al., 2017). Severe 
disabilities requiring residential care have become rare (Koch & de la Cruz, 1999), early-
treated adults typically lead independent lives (Koch et al., 2002) and neurocognitive 
outcomes generally fall close to or within normal ranges (Waisbren et al., 2007; Fonnesbeck 
et al., 2012; Beasley Costello & Smith, 1994; Azen et al., 1996). Despite these improvements, 
average neurocognitive outcomes among early-treated cohorts remain worse than healthy 
controls and siblings, the most informative comparators (DeRoche & Welsh, 2008; Enns et 
al., 2010). Neurocognitive outcomes also vary substantially (Waisbren et al., 2007; 
Fonnesbeck et al., 2012; Albrecht et al., 2009) and in some individuals intelligence remains 
low enough to affect education and employment prospects (Koch et al., 2002; Beasley 
Costetllo & Smith, 1994). Given the aforementioned links between control and 
neurocognitive outcomes, these below-normal neurocognitive outcomes would be expected 
to coexist with (and be partly attributable to) suboptimal control, which does remain 
common (figure 3). Few patients maintain it into adolescence, many adults cease treatment 
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altogether but most concerningly, many children lose control before ages 6-10 when it 
matters most (MacDonald, Nanuwa, Parkes, Nathan & Chauhan, 2011; Enns et al., 2010).  
Figure 3. Percentage of patients maintaining control or treatment at different lifestages 
 
Graph from Enns et al., (2010). Data from Walter et al., (2002). 
Whilst below-normal neurocognitive outcomes are most concerning, recent evidence 
suggests other aspects of health are commonly below-normal (and variable) in PKU 
including bone health, health related quality of life (HR-QoL), gastrointestinal comfort and 
adiposity levels (Enns et al., 2010; van Wegberg et al., 2017). This review next considers how 
limitations of conventional treatment may contribute to these suboptimal health outcomes 
and how a novel treatment called Glycomacropeptide may help. 
4.1: Dietary treatment is burdensome and compliance proves challenging. 
Practical treatment information comes from evidence-based guidelines that are not cited 
throughout (van Wegburg et al., 2017; Smith et al, 1993). Whilst treatment appears simple ( 
regulate phe intake) in practice therapeutic diets are restrictive as phe is ubiquitous in 
proteins meaning most protein-containing foods are restricted, even staples such as bread 
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and potatoes (table 3). Only very low-protein foods such as certain fruits, vegetables, fats 
and phe-free medical foods are consumable in normal quantities. 
Table 3. Dietary protein restriction during dietary treatment. 
High-protein foods.  Foods containing 
aspartame.  
Moderate-protein foods.  Low-protein foods.  
Cannot be 
consumed. 
Cannot be  
Consumed 
(metabolised to phe) 
Amounts consumable depend on 
severity/ tolerance. 
Exchange system expresses tolerance 
in food terms. 
Can be consumed in normal 
quantities.  
Excessive consumption may 
affect plasma phe. 
Meat, fish, eggs,  
most cheeses,  
nuts, seeds,  
soya, Quorn, tofu, 
bread products 
(containing flour). 
Certain fizzy drinks, 
squashes, cordials, 
desserts, crisps and 
chewing gums. 
 
Other artificial and 
natural sweeteners 
usually acceptable. 
Jacket potato    80g* 
Peas                    25g* 
Baked beans      20g* 
Corn flakes        15g* 
Milk                    30ml* 
*These quantities contain 1 exchange, 
which is 1g Protein & 50mg phe. 
Patients are assigned X exchanges per 
day based on their tolerance. 
Most fruits and vegetables.  
Fats such as butter and 
vegetable oils. 
Tea, coffee. Pure juice. 
Rice/ coconut milk. 
 
Specially manufactured, 
low-protein breads, pastas, 
biscuits, crackers. 
Adapted from table in previous assignment and Hallam, (2016). 
PKU diets are also complicated. The degree of dietary protein restriction required varies 
according to individual severity. This reflects residual PAH activity (Blau et al., 2010) though 
In practice  plasma phe monitoring and dietary adjustments are performed to determine the 
daily protein/ phe intake tolerable without  plasma phe leaving safe ranges (van Spronsen et 
al., 2009). This tolerance is communicated to patients via an exchange system (table 3). 
With protein intake restricted, Phe-free protein substitutes (formula) are prescribed to 
meet outstanding amino acid (AA) requirements. Tolerance and formula requirements 
change over the lifespan as protein requirements and sensitivity to plasma phe change, 
further complicating management. 
Given the restrictiveness and complexity of therapeutic diets, patients and parents find 
adherence difficult (MacDonald, Gokmen-Ozel, van Rijn & Burgard, 2010; Walter et al., 
2002) particularly with formula, poor adherence with which is noted at all lifestages via self-
reports (Schulz & Bremer, 1995; Macleod & Ney, 2010) and more objective measures 
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(Prince et al., 1997). This is primarily attributed to formula’s poor acceptability, particularly 
the taste, inconvenience and low social acceptability (MacDonald, Harris, Rylance, Asplin & 
Booth, 1997; Macleod & Ney, 2010) limitations that improved versions (e.g. ready-to-drink 
pouches) have not totally resolved (Macdonald et al., 2004; 2006; Prince et al., 1997). The 
burden of conventional treatment, particularly formula, is thus likely to contribute to the 
persistence of suboptimal control and neurocognitive outcomes. 
The persistence of poor control and suboptimal health outcomes despite near-universal 
treatment and the (apparently related) burden of conventional treatment explain 
continuing interest in novel treatments (reviewed by van Spronsen & Enns, 2010 and 
Specola & Chiesa, 2017) including GMP. 
4.2: Glycomacropeptide may improve several health outcomes. 
GMP is a 64 AA glycophosphopeptide released into bovine whey during cheese production 
and is the only intact protein naturally lacking phenylalanine (Van Calcar & Ney, 2012). 
Products manufactured from GMP form alternatives to formula that theoretically address 
several of its shortcomings and may improve suboptimal outcomes in PKU (see Ney & Etzel, 
2017 for review).  
4.2.1: Improved protein utilisation. 
GMP lacks some essential AAs, necessitating supplementation with some synthetic AAs (Van 
Calcar et al., 2009). Nevertheless, totally replacing formula with GMP  increases the intact 
protein content of diets markedly (from ~20% to ~70%) (Van Calcar & Ney 2012). This would 
be expected to improve protein utilisation as intact proteins are digested less rapidly and 
their AA reach plasma more slowly (Gropper & Acosta, 1991) decreasing oxidation (wastage) 
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and increasing protein utlisation/ synthesis (Metges et al., 2000). Findings of one short trial 
(showing decreased blood urea nitrogen, indicative of decreased ureagenesis) suggest 
protein utilisation improves as expected when replacing formula with GMP, though nitrogen 
balance and protein synthesis were not monitored (Van Calcar et al., 2009). Improved 
maintenance of bodily proteins, growth and adaptations to exercise may be expected to 
ensue over longer timeframes (Millward, Layman, Tomé, & Schaafsma, 2008) but are yet to 
be demonstrated. Improved control may also ensue as improved protein synthesis may 
incorporate more plasma phe into tissue proteins (the mechanism thought to explain how 
better adherence to formula improves control: see Macdonald et al., 2005). The effect of 
GMP upon control is complicated however and discussed later.  
 4.2.2: Satiety and excess adiposity. 
Persistent hunger is reported in PKU (MacLeod, Clayton, van Calcar & Ney, 2010) and 
obesity is common among females (Gokmen-Ozel et al., 2014). The causation of Obesity is 
complex (Rocha, Macdonald & Trefz, 2013) but the lack of intact protein in therapeutic diets 
may contribute as protein is the most satiating macronutrient (Greco et al., 2017) and even 
5% increases in intake improve long-term weight maintenance, partly as protein’s satiety 
displaces other macronutrients (Santesso et al., 2012; Clifton, Keogh & Condo, 2014). One 
short-term trial suggests GMP recreates the satiety of intact proteins better than formula 
(MacLeod et al, 2010) as would be expected. Therein, a GMP breakfast significantly 
increased subjective satiety, total plasma AA concentration and ghrelin suppression over 
formula. The metabolic changes induced are consistent with theoretical explanations for 
differences in satiety-promotion between nutritional factors (Greco et al., 2017). However, 
unblinding may have biased subjective satiety ratings as GMP tastes different. Moreover, 
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reduced food intake is yet to demonstrated over longer timeframes and may not occur 
(Poppitt et al., 2013) as appetite regulation is complex (Begg & Woods, 2013) and 
compensatory eating can occur (Benelam, 2009). 
4.2.3: Gastrointestinal symptoms. 
Formulas are hyperosmolar and may cause gastro-intestinal discomfort by drawing water 
into the digestive tract (van Wegberg et al., 2017) as non-digestible carbohydrates and 
enteric feeds can (Clausen, Jorgensen & Mortensen, 1998; Williams, 2008). GMP-based 
foods have lower osmolalities and may ameliorate symptoms (Ney & Etzel, 2017).  However, 
only uncontrolled studies (Macdonald et al., 1997) and qualitative reports (Ney et al., 2016) 
have linked symptoms to formula and improvements to GMP. Trials controlling for 
confounders including the type and dose of formula, other dietary constituents and innate 
susceptibility to gastrointestinal symptoms are required. Nevertheless, improved 
gastrointestinal comfort appears plausible. 
4.2.3: Bone health. 
Meta-analyses suggest the risk of impaired bone mineral density (BMD) is increased in PKU 
(Hansen & Ney 2014; Enns et al., 2010) though the strongest suggests only ~10% of cases 
reach clinical significance (Demirdas et al., 2015). Bone health in PKU is complex and poorly 
understood as most human studies are cross-sectional because formula cannot be ethically 
withheld for long periods during childhood. A study withholding formula in PKU mice (post-
weaning) suggests impairments are partly inherent to PKU but exacerbated by formula and 
partly rectified by GMP (Solverson, Murali, Litscher, Blank & Ney, 2012). Proposed 
mechanisms include improved synthesis of collagen, a protein constituent of bone (van 
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Wegberg et al, 2017) and the higher pH of GMP reducing skeletal buffering, which may 
resorb bone minerals to maintain acid-based homeostasis (Lemann, Bushinsky & Hamm, 
2003). However, BMD improvements are yet to be demonstrated in humans. 
4.2.4: Acceptability.   
The most consistently reported advantage of GMP over formula is greater acceptability, 
suggesting GMP addresses a major shortcoming of formula. Superior food making 
properties (e.g. heat stability) enable the production of a variety of more food-like products 
(Van Calcar & Ney, 2012). Resultantly, most patients consider GMP foods more palatable 
(Ney et al., 2016; Lim, van Calcar, Nelson, Gleason & Ney, 2007; Van Calcar et al., 2009; Zaki 
et al., 2016) and socially acceptable (Ney et al., 2016) than formula. It should be stressed 
that the strongest of these studies, a randomised crossover trial (Ney et al., 2016) selectively 
recruited patients finding GMP acceptable, potentially biasing results. Nevertheless, the 
weight of evidence suggests most subjects prefer GMP-based diets. Greater acceptability 
may improve HR-QOL, something formulas poor taste impacts upon (Bosch et al., 2015) but 
HR-QoL tools sensitive to PKU-specific difficulties have been validated only recently 
(Regnault et al., 2015) and trials are yet to utilise them. Greater acceptability may also 
indirectly improve control by promoting compliance with therapeutic diets, though the 
impact of GMP upon control is discussed shortly. 
GMP products are yet to elicit improvements in any long-term health outcome in a 
controlled trial. However, this is partly  relates to constraints upon the types of study 
practicable. The low prevalence of PKU makes attracting funding and recruitment difficult, 
particularly for long-term trials, formula cannot ethically be withheld during childhood and 
GMP foods were only recently applied to PKU (~2009). Whilst clearly requiring confirmation, 
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each of the proposed advantages is theoretically plausible, supported by preliminary data 
and has the potential to improve therapeutic diets and reduce the burden of PKU.  
 
5.0: The effect of GMP on control is poorly understood, raising concern. 
Given the importance of control, GMPs impact upon it is paramount. Whilst improved 
control may address suboptimal neurocognitive outcomes, equivalent control to formula 
would constitute a positive finding given GMP’s other advantages. However, GMPs effect on 
control is complicated as, whilst GMP is naturally phe-free, commercially viable purification 
processes leave GMP contaminated with residual phe from other whey constituents (Ney & 
Etzel 2017; La Clair, Ney, Macleod & Etzel  2009). Commercial GMP products contain ~1.8 
mg phe per gram protein (Ney et al., 2016; Vitaflo, 2017) raising safety concerns, particularly 
among children that tolerate less phe. As the most recent evidence-based guidelines 
acknowledge (van Wegberg, 2017) these concerns remain unresolved. 
5.1: Effect on control in adults (over 16).   
In adults, every study this non-systematic review located administered GMP identically. 
GMP totally replaced formula then the additional phe introduced was compensated for by 
reducing exchanges so diets contained equal phe (Van Calcar & Ney, 2012). A mouse study 
(Ney, Hull, van Calcar, Liu & Etzel, 2007) and case study (Ney et al., 2009) suggest GMP 
improves control over formula by ~10% (average) despite diets containing equal phe. 
Improvements are attributed to three mechanisms. GMP naturally contains more threonine 
and isoleucine than other proteins (Ney et al., 2009) and these LNAA may decrease 
intestinal phe absorption by competitively inhibiting LAT-1 transporters as LNAA treatment 
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does (Sanjuro et al., 2003; Matalon et al., 2006; 2007). The formulation of GMP used in 
these studies and others by Ney & colleagues (Glytactin) is also supplemented to contain 
higher quantities of other LNAA (otherwise limiting in GMP) than formula (150% of USA RDI 
for Tyrosine, 130% for other limiting LNAA). Secondly, GMPs greater acceptability may 
improve compliance in free-living subjects. Compliance with protein substitutes involves 
consuming sufficient quantities (Macdonald et al., 2005; Duran et al., 1999) and distributing 
‘doses’ over 3-4 meals, which both promote control by increasing protein utilisation to 
move more plasma phe into tissue proteins (Mönch, Herrmann, Brösicke, Schöffer & Keller, 
1996; MacDonald et al., 1996). Compliance with the wider therapeutic diet prevents the 
consumption of excess phe-containing foods and inadequate energy, which causes 
catabolism and mobilises phe from tissue proteins. The case study participant reported 
greater compliance with the GMP diet, citing its acceptability (Ney et al., 2009). Finally, GMP 
may improve protein utilisation over formula, incorporating more plasma phe into tissue 
proteins (section 3.2.1). Ensuing control improvements may improve cognitive outcomes or 
increase tolerance, permitting dietary relaxation.  
Control improvements have not been recreated in controlled trials, however. A self-
controlled inpatient trial (van Calcar et al., 2009) and a randomised, crossover involving 
outpatients (Ney et al., 2016) both reported no significant difference in control after GMP 
replaced formula. The discrepancy in findings remains unexplained. It may relate to the 
mouse model and single subject employed in earlier studies poorly representing PKU 
populations or bias in the earlier, weaker studies. Bias is minimised by design features like 
randomisation which tend to cluster in stronger studies (Deeks et al., 2003) and generally 
(though not always) overstates an interventions benefit (Higgins, Altman & Sterne, 2008). 
27 
 
Heterogenity may also contribute. For example, the improvements in compliance and 
control noted among free-living subject(s) by Ney et al., (2009) but not Ney et al., (2016) 
may relate to the former study comparing ready-to-eat, food-like GMP products to 
powdered formulas requiring weighing and preparation, whilst the later study mainly 
compared GMP to ready-to-drink liquid formulas that form a stronger control as they are 
more acceptable (Macdonald et al., 2004; 2006). Different plasma phe assessment methods 
may similarly influence results (Gregory, Yu & Singh 2007). Nevertheless, it must be stressed 
that the broadly equivalent control demonstrated is a positive finding given GMPs other 
advantages.  
Additional studies are required to confirm this as only two controlled human trials with 
limitations were located. One administered GMP for only 4 days, lacked randomisation and 
used an inpatient setting lacking ecological validity (van Calcar et al., 2009). The strongest 
(Ney et al., 2016) purposively recruited patients finding GMP acceptable, potentially biasing 
results. It also demonstrated maintenance of control despite the GMP condition providing 
88 ± 6mg/ day additional phe as dietary exchanges were not reduced to compensate in the 
GMP condition. This may be interpreted as suggesting ‘control would be equivalent if 
patients complied’. However, difficulties removing exchanges are concerning and may 
compromise control in some individuals. In addition, every GMP-centric review (Van Calcar 
& Ney, 2012; Ney, Blank & Hansen, 2014; Ney & Etzel, 2017) and primary study previously 
cited are from one group with commercial interests in GMP products (see conflicts of 
interest in Ney et al., 2016) raising objectivity concerns (Oxman & Guyatt, 1993). These 
reviews have not specifically investigated GMP’s effect on control and are narrative so have 
not synthesized or evaluated the entire evidence base using transparent, systematic 
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methods such as those of the Cochrane collaboration (Green et al., 2011) and PRISMA 
(Liberati et al., 2009) which evaluate the contribution of bias (Mulrow, 1994; Oxman & 
Guyatt, 1993) to results. There is therefore need for such a review, to clarify the effect of 
GMP upon control in adults (over 16). It should also clarify GMPs effect upon compliance, 
particularly whether GMP promotes compliance and whether non-compliance may 
compromise control in some cases.  
5.2: Effect on control in children (3 - 16).   
GMP foods contain excessive phe and insufficient energy for children under three (van 
Calcar et al., 2012). However, several have approval for older children in England 
(Cambrooke, 2018; Vitaflo, 2017) despite their effect upon control remaining controversial. 
Children require more protein (per kg BM) than adults for growth (WHO, 2007) but tolerate 
less phe (table 6) so formula constitutes more of their diets (van Calcar et al., 2012). The 
substitution method used in adults (100% replacement) appears unsuitable as the phe 
introduced can be excessive given the lower tolerances and that insufficient exchanges are 
consumed to remove in compensation. Studies involving children have instead investigated 
partially replacing formula with GMP, though only three were located. In one, control was 
maintained on average when comparing 50% GMP & 50% formula to 100% formula over 
nine weeks (Zaki et al., 2016). Another reported improved control when replacing formula 
with GMP for 3 days in infants, children and adults (Abdel-Salam & Effat, 2010). However, 
both lack randomisation and pilot-test incomplete GMP formulations differing from 
commercial products in their organoleptics, LNAA content and phe content. Both 
manuscripts also omit important details such as compliance data and the type of formula 
used.  
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Whilst Zaki et al., (2016) reported equivalent control after replacing the same proportion of 
formula with GMP in each individual (50%) another study used a different approach. 
Individualised titrations (adjusting the amount of formula replaced by GMP) were necessary 
to maintain control during a six month study (Daly, Evans, Chahal, Santra & MacDonald, 
2017) in which ethics precluded control loss. The average replacement possible was 50% 
(agreeing with Zaki and colleagues) though the amount varied from 30 to 100%. This 
suggests maintenance of control depends on individualised adjustments though the design 
was similarly limited. Again a preliminary form of GMP was used though a self-controlled 
design was not.  These are standard in PKU as between-subject comparisons of plasma phe 
are problematic since tolerance, intensity of treatment and baseline control vary. 
Comparisons with retrospective control data collected under non-experimental conditions 
were thus necessary, potentially introducing confounding.  
Overall, the effect of GMP on control in children is less well understood than in adults 
despite GMP being licenced for use in this group and control being crucial. This informal 
review noted only three pilot studies using heterogeneous, bias-prone designs, poor 
reporting and preliminary GMP formulations. These suggest maintenance of control in 
children is possible following GMP substitution provided individual-level adjustments are 
performed but the suggestion requires confirmation, ideally through randomised, controlled 
longitudinal trials with self-controlled designs, that perform patient-level adjustments if 
required. A systematic review is required to clarify GMPs impact on control in children. It 
should use methods mirroring those described in adults to synthesize the entire evidence 
base then consider the contribution of design quality, bias, heterogeneity and compliance to 
results. Ideally, the review should describe inter-individual variation in phe responses (of the 
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amount of formula safely replaceable with GMP) and identify their determinants, as this 
may help to direct treatment.  
6.0: Conclusion. 
Before treatment was discovered PKU was associated with severe neurocognitive deficits 
requiring residential care. Treatment restricts dietary phenylalanine to control plasma phe, 
preventing its accumulation to toxic levels. As the developing CNS is most vulnerable to phe, 
treatment is initiated at birth and stricter control is essential during childhood but lifelong 
adherence is universally recommended as defects occur with later cessation. Since the 
widespread adoption of dietary treatment the severe disabilities previously seen have 
become rare but intelligence and other aspects of health remain below-normal even among 
early-treated patients, partly as dietary treatment has limitations. Adherence proves 
difficult as therapeutic diets are restrictive, complicated and formulas lack acceptability. 
GMP is a novel alternative to formula that emerging evidence suggests has the potential to 
improve therapeutic diets and patients health in several ways. However, GMP contains 
some phenylalanine raising concerns around its impact on control, particularly among 
children. Despite GMP having UK approval for over 3s, these concerns remain unresolved 
and the recent European evidence-based guidelines offer no advice regarding GMP use. 
The evidence reviewed herein suggests adults generally maintain control after GMP replaces 
formula, a supportive finding given GMPs many advantages. This requires confirmation 
however, as only two controlled trials were located. One was unrealistically short, the other 
suffered dietary compliance problems that may impair control in some individuals and both 
had heterogeneous designs. Existing reviews are similarly limited and come from one group 
commercially linked to products, raising objectivity concerns. None specifically consider 
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control and all are narrative, suggesting bias may affect conclusions.  A systematic review is 
thus necessary to clarify the effect of GMP on control in adults by synthesizing and 
evaluating the entire evidence base using pre-determined methods to consider the 
contribution of design quality, bias, heterogeneity and compliance levels to results. It should 
also clarify the utility partially replacing formula with GMP in adults. 
GMPs effect on control in children is less clear, which is concerning given the importance of 
childhood control. Only three, small preliminary studies were located, most with poor 
reporting and all with bias-prone, heterogeneous designs that administered preliminary 
GMP formulations unrepresentative of those used clinically. Taken together, they suggest 
maintenance of control is possible following partial replacement of formula with GMP in 
children but the proportion of formula replicable without control loss is likely to vary 
individually, necessitating individualised monitoring and adjustments. However given the 
few, limited studies reviewed, a systematic review mirroring that described for adults is 
necessary to clarify matters. It should ideally attempt to describe and explore inter-
individual variation in responses to inform practice (e.g. by helping to direct treatment).  
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0.0: Journal selection  
The European Journal of Clinical Nutrition (https://www.nature.com/ejcn/) was selected for 
publication. Dietary therapies meet its scope, it publishes PRISMA-compliant systematic 
reviews without requiring prospective protocol registration (something overlooked), 
decisions regarding acceptance are quick (~47 days) and publication online is rapid (~25 
days). The journal is also widely indexed to increase visibility. The journal’s low impact factor 
(2.954) when compared to leading nutrition journals such as the American Journal of Clinical 
Nutrition (Clarivate, 2018) will reduce visibility but an inconclusive review concerning a rare 
disease by a student would likely be rejected by a journal like this with a low acceptance 
rate (20%) and highly competitive publication process (AJCN, 2018). The journal’s formatting 
requirements resemble the university’s (e.g. 5000 word limit, 8 table maximum) so only 
minor adaptations will be required (e.g. referencing).  
 
0.1: Abstract. 
Background: Conventional phenylketonuria (PKU) treatment controls plasma phenylalanine 
concentrations (henceforth: plasma phe) by restricting intake of phenylalanine (phe) from 
protein-containing foods and prescribing amino acid-based 'formula’ to meet protein 
requirements. Glycomacropeptide-based foods form novel alternatives to formula that may 
improve satiety, acceptability and compliance. However, glycomacropeptide (GMP) contains 
some phenylalanine raising concerns regarding its impact upon plasma phe in adults and 
particularly children, who tolerate less phenylalanine.  
Objectives: To clarify GMPs effect upon compliance and control in adults and children with 
phenylketonuria.  
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Methods: Identical PRISMA-compliant systematic reviews were conducted for adults (over 
16) and children (3 – 16). They largely considered any controlled, human study comparing 
GMP to formula acceptable, including non-randomised studies. Multiple databases, 
registries, grey literature and snowballing methods were utilised. The Cochrane risk of bias 
tool and GRADE were adapted to evaluate studies and structured, narrative analyses used. 
Results (adults): Six studies were included but conclusions were based upon the sole high-
quality randomised trial to avoid bias. It suggests control will deteriorate by ~10% on 
average if GMP totally replaces formula, but notes marked inter-individual variation in 
responses (from ~200 µmol/L improvement to ~400 µmol/L deterioration) that remains 
unexplained. As patients finding GMP acceptable were selectively recruited and allowed to 
self-select GMP foods, less optimistic responses may occur under less ideal conditions. No  
compelling evidence of compliance improvements was located and the control decreases 
described partly related to compliance difficulties as every patient failed to reduce dietary 
protein intake to accommodate the phe in GMP.  
Results (children): The two studies included together suggest formula cannot be totally 
replaced by GMP in all children without control leaving safe ranges. The amount ‘safely 
replaceable’ varied from ~30 – 100%, suggesting control monitoring and adjustments are 
necessary in practice. However, both studies had extremely limited, heterogeneous designs 
susceptible to bias, confounding, measurement error and neither monitored compliance 
adequately. Moreover, both used preliminary GMP formulations with different LNAA (Large 
Neutral Amino Acid) and phe contents from commercial products, something likely to 
decrease effectiveness.  
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Conclusions: The review was unable to describe GMPs effect upon compliance and control 
with any certainty. Caution is thus advised among practioners choosing to prescribe GMP, 
particularly to children, until additional randomised trials are conducted to clarify matters. If 
GMP is utilised, products high in LNAA and low in phe should be selected (e.g. Glytactin), 
control and compliance should be monitored carefully and in children practioners should be 
prepared to adjust the amount of GMP introduced if control leaves safe ranges.  
1.0: Introduction. 
Phenylketonuria impairs Phenylalanine Hydroxylase functionality, causing Phe to 
accumulate to toxic levels in plasma and tissues (Blau, van Spronsen & Levy, 2010). Prior to 
the development of dietary treatment, PKU was associated with severe neurocognitive 
disabilities usually requiring residential care (Paine, 1957). Dietary treatment is initiated at 
birth and restricts dietary phenylalanine to control plasma phe (van Wegburg et al., 2017). 
Overwhelming evidence supports its effectiveness (Waisbren et al., 2007; Fonnesbeck, 
McPheeters, Krishnaswami, Lindegren & Reimschisel, 2012; Albrecht, Garbade & Burgard, 
2009) and since its widespread adoption the disabilities previously commonplace have 
become rare and most treated patients lead normal lives (Koch et al, 2002).  
However, treatment has limitations. As phenylalanine is ubiquitous in proteins most 
protein-containing foods must be restricted, even staples (van Wegburg et al., 2017). 
Moreover the phe-free protein substitutes (formula) prescribed to address protein 
requirements lack acceptability & convenience (MacDonald, Harris, Rylance, Asplin & Booth, 
1997; Macdonald, 2000), limitations that improvements have not totally resolved (Prince, 
McMurry & Buist, 1997; Macdonald et al., 2004). As a result, adherence proves difficult in all 
ages (MacDonald, Gokmen-Ozel, van Rijn & Burgard, 2010; Walter et al., 2002) particularly 
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with formula (Schulz & Bremer, 1995; Prince et al., 1997). As adherence improves control 
(Macdonald et al., 2006; Mönch, Herrmann, Brösicke, Schöffer & Keller, 1996) and control 
predicts neurocognitive outcomes (Waisbren et al., 2007; Fonnesbeck et al., 2012) these 
limitations of treatment likely contribute to poor control and below-normal neurocognitive 
outcomes remaining commonplace among early-treated patients (DeRoche & Welsh, 2008; 
Enns et al., 2010). They also explain interest in alternative treatments (van Spronsen & Enns, 
2010; Specola & Chiesa, 2017) including Glycomacropeptide. 
Glycomacropeptide (GMP), the only naturally phe-free intact protein, is used to 
manufacture foods forming alternatives to formula (Van Calcar & Ney, 2012). Emerging 
evidence suggest these have the potential to improve the palatability (Ney et al., 2016; Lim, 
van Calcar, Nelson, Gleason & Ney, 2007; Van Calcar et al., 2009; Zaki et al., 2016) and 
satiety (MacLeod, Clayton, van Calcar& Ney, 2010) of PKU diets and may also improve bone 
health (Solverson, Murali, Litscher, Blank & Ney, 2012) and gastrointestinal comfort over 
formula (Ney et al., 2016). As patients attribute compliance difficulties to the poor 
palatability and satiety of formula, compliance and control improvements may be expected 
to ensue. However, as purification methods are imperfect, GMP contains residual 
phenylalanine (La Clair, Ney, Macleod & Etzel  2009) raising concerns regarding its impact on 
control, particularly among children that are more susceptible to phe. Despite GMP 
products having UK approval for children (Cambrooke, 2018; Vitaflo, 2017) the most recent 
evidence-based guidelines acknowledge that these concerns remain unresolved (van 
Wegberg, 2017).  
A non-systematic review  was conducted to clarify matters but was unsuccessful. It located 
three studies comparing GMP to formula in adults (over 16). One reported improved control 
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(by 10%) and compliance on GMP (Ney et al., 2009). Another (van Calcar et al., 2009) 
reported equivalent control, a supportive finding given GMP’s other advantages. However, 
both had limited designs. The former was a case study meaning the subject may be an 
outlier. The latter was unrealistically short, lacked randomisation and used an inpatient 
setting, preventing compliance differences from occurring. The strongest study located was 
randomised and (conversely) reported ~10% worse control on average alongside 
compliance difficulties (Ney et al., 2016). This suggests bias may explain previous supportive 
findings and raises concerns regarding GMP’s impact upon compliance and control in adults. 
As findings were conflicting, these concerns require clarification, particularly as the review 
did not use pre-determined methods to review the entire evidence base in an unbiased 
manner or formally evaluate the contribution of heterogeneity or bias to results (Mulrow, 
1994; Oxman & Guyatt, 1993) as a PRISMA-compliant systematic review would (Liberati et 
al., 2009). Existing GMP reviews have similar limitations (Van Calcar & Ney, 2012; Ney, Blank 
& Hansen, 2014; Ney & Etzel, 2017), come from one group with commercial interests in 
GMP raising objectivity concerns (Oxman & Guyatt, 1993) do not specifically consider 
compliance or control and require updating. A PRISMA-compliant systematic review was 
thus performed to clarify GMPs effect on control (objective 1a) and compliance (objective 
1b) in adults. 
The review located three studies involving children (3 – 16). Whilst control findings were 
conflicting, heterogeneous approaches to replacing formula with GMP were used, making 
comparisons difficult. Abdel-Salam & Effat, (2010) reported questionable control 
improvements (30 – 80% over 3 days) and poor reporting left the amount of formula 
replaced unclear. Zaki et al., (2016) replaced 50% of formula and reported equivalent 
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control. Daly, Evans, Chahal, Santra & MacDonald, (2017) adjusted the amount of formula 
replaced on an individual basis to prevent control leaving safe ranges for ethical reasons, 
and replaced 30 – 80%. Furthermore, all had non-randomised, bias-prone designs, unclear 
reporting and pilot-tested incomplete GMP formulations poorly representing those used 
clinically. As only three studies with conflicting findings and heterogeneous, low quality 
designs were located, GMPs effect upon compliance and control in children is poorly 
understood, despite control being crucial (van Wegberg et al., 2017). An identical systematic 
review was thus performed to clarify the effect of GMP upon control (objective 2a) and 
compliance (objective 2b) in children. 
 
2.0: Methods. 
2.1: Overall approach 
Methods were selected using guidance from the Cochrane Collaboration (Higgins, Churchill, 
Chandler & Cumpston, 2017) and Centre for Reviews & Dissemination (CRD, 2009). 
Reporting met PRISMA requirements (Moher et al., 2009) and a PRISMA-P compliant 
protocol was prepared prospectively (appendix 3) to ensure transparency (Shamseer et al., 
2015).  
2.2: Eligibility criteria 
Given the few, low-quality studies previously located, eligibility criteria (tables 19-20) 
favoured inclusivity. Most controlled human studies comparing GMP to formula were 
eligible, including non-randomised studies (NRS), despite the likelihood of this increasing 
heterogeneity and bias.  
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2.3: Search Strategy 
For details of resources searched & terms used see tables 12-18 (appendix 1). A librarian 
assisted with search strategy development. To increase sensitivity, multiple databases were 
utilised alongside snowballing methods including hand searches of key journals (Suarez-
Almazor, Belseck, Homik, Dorgan & Ramos-Remus, 2000), reference list searches of key 
articles and several citation search tools. To counteract publication bias, unpublished 
literature and registries were included (Song, Eastwood, Gilbody, Duley & Sutton, 2000) but 
as translation facilities were unavailable non-English studies were excluded, risking language 
bias (Egger et al., 1997). A PubMed search strategy (table 12) was devised first by adapting 
Cochrane’s  IEM strategy (Cochrane, 2018). To favour sensitivity, only the condition (PKU) 
and intervention (GMP) aspects of PICOS were combined using ‘AND’, but many synonyms 
for each were combined using ‘OR’ (CRD, 2009). Natural language was preferred over 
database-specific terms to expediate adaptation for other databases and because these can 
be mis-applied (Relevo & Balshem, 2011). The strategy was pilot-tested, adapted for other 
resources and checked against peer-reviewed guidance (McGowan et al., 2015). 
2.4: Data management, screening & data extraction 
Data was managed using EndNote, tables 12-18 and a PRISMA flowchart (figure 1). After 
duplicate removal, abstracts and titles of studies located using database-type resources 
(tables 12-14) were screened (table 19). Screened studies then directed searches of 
snowball-type resources (tables 15-18). Different reports of the same study were next 
merged but retained to check for selective reporting (CRD, 2009). Remaining full text articles 
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were checked against inclusion criteria (table 20) and exclusions explained (table 7).  Data 
required to address objectives, describe methods and evaluate quality was extracted using 
standard forms (table 21). Authors were emailed regarding missing data (table 22) and 
allowed 18 days to respond though studies were included irrespective of responses. All 
forms were developed using PICOS (Participants, Intervention, Control, Outcome, Study 
design) a-priori to minimise bias, piloted and their completion was double-checked to 
reduce errors as repetition by another reviewer (Higgins & Deeks, 2011) was unavailable. 
2.5: Quality evaluation of individual studies 
The Cochrane risk of bias tool (Higgins, Altman & Sterne, 2017) was adapted to evaluate 
study quality. Unlike numerical scales and checklists (Crowe & Sheppard, 2011; Moher et al., 
1995) this ensures reviewers transparently explain decisions, consider the importance of 
each bias form to their review’s topic (table 2), consider the likely magnitude and direction 
of bias and distinguish conduct (which risks bias) from reporting (Higgins et al., 2011). The 
tool was adapted to incorporate within-subjects designs (common in PKU) via a carryover 
domain (Higgins, Deeks & Altman, 2011). Non-randomised studies were considered at risk of 
selection bias irrespective of the apparent distribution of confounding variables or attempts 
to balance them (Deeks et al., 2003) but otherwise evaluated like randomised studies (RS) 
(Reeves, Deeks, Higgins & Wells, 2011). The tool was expanded to evaluate aspects of design 
quality not relating to bias such as sample size & precision (which quantitative meta-
analyses incorporate), measurement errors and external validity as these also reduce 
confidence in findings (CRD, 2009). 
2.6: Data analysis 
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Given the bias-prone, heterogeneous studies previously located, quantitatively pooling 
results may have attached unwarranted credibility to findings and mislead readers (CRD, 
2009; Deeks, Higgins & Altman, 2017). Narrative analyses were instead performed using 
structured approaches (CRD 2009, page 45; Popay et al., 2006). Separate analyses were 
performed for adults (over 16) and children (3-16) since phe  tolerance, protein and formula 
requirements differ (van Wegberg et al., 2017) and totally replacing formula with GMP 
appears impossible in some children (Daly et al., 2017). Quality assessments were 
incorporated into analyses through tables (3 & 8) comparing effect estimates to study 
limitations. To avoid misleading findings due to bias randomised/ high quality studies were 
analysed separately and conclusions based primarily on them, where possible (Reeves et al., 
2011). The contribution of heterogeneity to results was evaluated using narrative subgroup-
analyses which grouped studies by potentially mediating characteristics and compared 
effects (Popay et al., 2006). Possible mediators of responses were listed a-priori though no 
hypotheses were formed regarding them.  
 2.7: Review-wide quality evaluation. 
The confidence that can place in conclusions was rated using GRADE (Guyatt et al., 2011). 
Risk of publication bias was evaluated subjectively as compatible precision data for funnel 
plots/ statistical tests was unavailable due to poor reporting. The approach recreated a 
funnel plot by comparing the number of small, industry-linked, supportive studies and small 
unsupportive studies (CRD, 2009). 
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3.0: Results 
Figure 1: PRISMA flowchart of review process. 
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Table 1a: Characteristics of included adult studies. 
 
Study Methods Participants Intervention (GMP) & control (AA) Measurements taken Notes 
LaClair et 
al., (2009) 
Early study primarily investigating 
the purification and  
supplementation of GMP to form a 
complete Amino acid (AA) source. 
Secondarily monitored control in a 
subset of n = 4 (from 15) subjects 
sequentially undergoing 4 days usual 
treatment (formula) then  4 days 
GMP treatment in a non-
randomised, self-controlled, within-
subjects design.  
Number: 4 
Ages: 19-29 
Population: unknown 
Severity: unknown 
History: unknown 
Setting:  outpatient 
Country: USA 
GMP formats: Pudding  (food-like) 
Phe content: unknown 
LNAA content: High vs formula (150% 
of USA Recommended Daily intake 
(RDI) for Tyrosine, 130% for other 
limiting LNAA) 
Nutritionally complete: Yes 
Commercial product: No 
% formula replaced: 100% 
Exchanges removed? Yes, diets 
contained equal phe 
Same GMP in every patient: yes 
AA formats: Unknown 
Same formula in every patient: No  
Timepoints measured:  
Single, post prandial 
measurement 2.5h after 
breakfast on final 2 days of 
each 4 day condition. 
Collection and analysis: 
Plasma samples obtained via 
venepuncture, analysed via 
Beckman 6300 amino acid 
analyser (ion exchange 
chromatography). 
Many aspects of design  
remain unclear as published 
report lacked detail and no 
response  was received to 
request for clarification. 
Ney et al., 
(2009) 
Non-randomised experimental case 
study comparing usual treatment 
(formula) to GMP over 15 weeks in n 
= 1 outpatient. Formula was 
consumed  for the first 3 weeks and 
last 2 weeks, and GMP for the middle 
10 weeks but data is reported  for 6 
weeks during which weighed, 
portioned food of known phe 
content was provided (2 weeks 
formula & 4 weeks GMP).  
Number: 1 
Age: 29 
Population: clinic 
patient 
Severity: Classical 
History: on-diet but 
lapsed as adolescent 
Setting:  outpatient 
Country: USA 
GMP formats: sports drink, milkshake, 
puddings, snack bar (food-like) 
Phe content: 0.4g/ 100g GMP  
LNAA content: As above 
Nutritionally complete: Yes 
Commercial product: No 
% formula replaced: 100% 
Exchanges removed? Yes, diets 
contained equal phe 
Same GMP in every patient: yes, n=1 
AA format: weighed powder 
Same formula in every patient: n=1 
(a) Plasma samples: collected 
via venepuncture (fasting) 
between 12:00 to 12:30 at local 
clinic. 4 samples collected over 
GMP and formula conditions. 
Analysed via Beckman 6300 AA 
analyser.  
(b) Bloodspots: collected by 
patient from 9.00-9.30 (fasting). 
8 samples collected in GMP 
condition, 4 in AA condition. 
Analysed via tandem Mass 
spectrometry. 
Full details available as 
response was received to 
request for clarification. 
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Table 1b: Characteristics of included adult studies (continued). 
 
Study Methods Participants Intervention (GMP) & control (AA) Measurements taken Notes 
van Calcar 
et al., 
(2009) 
Inpatient metabolic study with non-
randomised, within-subjects design. 
 n=11 patients underwent 4 days 
usual treatment (AA) then 4 days 
GMP treatment in a non-randomised 
order. Subjects were inpatients for 
days 2-4 of AA treatment and all four 
days of GMP treatment.  
Number: 11 
Age: 11-31 (n = 3 < 16) 
Population: clinic 
patients 
Severity: 10 Classical, 1 
variant (>1000 µmol/L) 
History: early treated. 
No other details. 
Setting:  outpatient 
Country: USA 
GMP formats: sports drink, milkshake, 
pudding, snack bar (food-like) 
LNAA content: High vs formula (150% 
of USA RDI for Tyr, 130% for other 
limiting LNAA) 
Phe content: As above 
Nutritionally complete: Yes 
Commercial product: No 
% formula replaced: 100% 
Exchanges removed? Yes, diets 
contained equal phe 
Same GMP in every patient: no 
AA format: mainly weighed powder 
Same formula in every patient: no 
Data presented compares 
postprandial (n=11) and fasting 
(n=6) plasma phe data for final 
day of each condition (days 4 vs 
8). Analysis is via Beckman 6300 
AA analyser. Fasting data 
collected only in subset of n=6 
patients. 
Data was collected for the final 
2 days of each condition (3 vs 7 
& 4 vs 8) but data from  days 3 
& 7 were omitted due to space 
constraints in the journal. This 
does not affect findings. 
Full details available as 
response was received to 
request for clarification. 
Ney et al., 
(2016) 
Randomised, two-centre crossover 
trial comparing control in n=30 free 
living outpatients during 3 weeks 
usual treatment (formula) and 3 
weeks GMP treatment, separated by 
a 3 week washout on formula. 
Number: 30 
Age: 15 - 49 
Population: PKU 
patients at 2 centres 
Severity: 20 Classical, 
10 variant. 
History: early treated. 
optimal control not 
required. 
Setting:  Outpatient 
Country: USA 
GMP formats: Food-like (e.g. pudding). 
Phe content: 1.8 mg/ g PE (foods) 
LNAA content: As above 
Nutritionally complete: Yes 
Commercial product: Yes, Glytactin. 
% formula replaced: 100% 
Exchanges removed? Yes, diets 
designed to contain equal phe 
Same GMP in every patient: no, self-
selected favourite format 
AA format: mix of food-like and 
weighed powder. Some took both. 
Same formula in every patient: no. 
(a) For the main effect, 4 fasting 
venous blood samples were 
taken during study visits: (1) 
baseline pre-AA (2) end of AA 
(3) baseline pre-GMP (4) end of 
GMP. Analysed via Hitachi L-
8900 amino acid analyser. 
(b) Secondary analyses used 
dried blood spots taken at 8 
points during each 3 week 
treatment period (on days 3, 6, 
7, 10, 13, 14, 17, 21). Analysed 
via tandem MS. 
Full details available as 
response was received to 
request for clarification. 
 
NB. Five subjects (with variant 
PKU) completed the study 
whilst taking Sapropterin 
treatment. However, their 
phe tolerance was stable at 
baseline and the Sapropterin 
dose remained consistent 
throughout. 
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Table 1c: Characteristics of included adult studies (continued). 
 
Pinto et 
al., (2017) 
Observational study that 
retrospectively compares 
longitudinal control data from n=11 
patients undergoing periods of AA 
(13 ± 5m) and GMP treatment (13 ± 
7 m) during routine clinical practice. 
The amount of formula replaced by 
GMP varied (27-100%) according to 
choice or assignment by clinicians: 
mean 57% (27 – 100%). 
Number: 11 
Age: Mean = 27  
(n=1 <16: 13 years old). 
Population: Struggling 
to maintain control. 
Severity: 1 HPA, 4 
mild, 6 classical 
History: Unknown 
Setting:  Outpatient 
Country: Portugal 
GMP formats: Mainly weighed powder 
Phe content: 1.7mg/ g PE (foods) 
LNAA content: As above 
Nutritionally complete: Yes 
Commercial product: Yes, Glytactin. 
% formula replaced: 27-100%  
Exchanges removed? No. GMP diet 
contained extra phe (34 ± 12 mg) 
Same GMP in all patients: all but one  
AA format: mix of food-like and 
weighed powder. Some took both. 
Same formula in every patient: no. 
Control monitored via fasting 
blood spot collection: 
i) Formula comparator: median 
of 11 blood spots taken from 
May 2013 until GMP 
introduction (13 ± 5 months)     
ii) GMP intervention: median of 
15 blood spots taken from GMP 
introduction until the second 
evaluation  (13 ± 7 months). 
Analysed via tandem MS. 
 
 
Ahring et 
al., (2018) 
Short-term, single blinded, 
randomised crossover trial 
comparing the effect of four drink 
mixtures (consumed with a standard 
meal) on postprandial plasma phe  
for 240 minutes after ingestion in 
n=8 subjects.  Comparison 1: Pure 
GMP (Lacprodan CGMP-20) vs 
formula with the same AA profile. 
Comparison 2 (of interest): GMP  
supplemented with limiting AA  to 
form complete protein source vs 
formula  with the same AA profile, 
minus phe. 
Number: 8 
Age: 16 – 48 (mean 33) 
Population: Recruited 
via national database 
Severity: all Classical 
History: early  & 
continuously treated.  
Setting:  Attended 
centre 4 times (for 
each drink) 
Country: Denmark  
GMP format: drink compositions in 
first column 
Phe content: GMP = 0.16 g Phe/ 100 g 
AA  
LNAA content: Unclear 
Nutritionally complete: Drink 3 was. 
Commercial product: No. 
% formula replaced: 100% for 1 meal 
Exchanges removed?  No, only 
investigated 1 meal 
Same GMP in every patient: yes (for 1 
meal) 
AA format: drinks, see first column 
Same formula in every patient: yes 
On each of four visits (one for 
each drink) venous blood was 
collected as follows: 
(a) fasting samples taken in the 
morning (0 minutes, baseline)  
(b) the meal was consumed 
(c) postprandial samples were 
taken 15, 30, 60, 120, and 240 
minutes after the meal. 
 
Analysis was via HPLC-MS/ MS 
Some details unknown as no 
response was received to a 
request for clarification. 
y = year, m = month, HPLC = high performance liquid chromatography, MS = mass spectrometry 
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Table 2a: Identification of important quality domains. 
Domain Importance Explanation Likely direction and magnitude of bias 
Random 
sequence 
generation (1) 
High In parallel designs, prevents selection bias I.E. systematic differences in the distribution of 
prognostic factors between groups which may confound changes in control otherwise 
attributable to the intervention or comparator (Higgins et al., 2017). 
Within-subjects designs are common in PKU to control for between subject differences 
(e.g. in severity). In these, randomisation instead prevents confounding from order effects 
and trends in outcomes over time. It is unclear how these would occur in PKU but only 
adequate randomisation accounts for unknown factors (Reeves, Deeks, Higgins & Wells 
2011). 
Generally overstates benefit of GMP. 
Varies (Odgaard-Jensen et al., 2011) but 
results are generally overly-optimistic where 
randomisation is inadequate as subjects 
likely to respond well tend to be 
preferentially assigned/ select the  
intervention or a treatment order (Savovic 
et al., 2012). 
Concealment of 
allocations (2)  
High  Serves the same purpose as random sequence generation. Personnel aware of upcoming 
allocations may preferentially assign subjects to particular treatments (parallel studies) or 
treatment orders (within-subject studies). Concealment of allocations prevents this. It is 
distinct from blinding which occurs after randomisation.. 
Generally overstates benefit of GMP. 
As above. 
Blinding of 
participants & 
Personnel (3) 
Low Prevents participants and personnel gaining awareness of allocations to prevent 
performance bias. I.E. systematic differences between conditions in the care provided or 
exposure to confounding factors.  Blinding of participants is unimportant as GMP tastes 
different from formula and the possibility of this promoting compliance improvements is 
being investigated. Blinding of personnel is also unimportant. It is difficult as GMP and 
formula look different and unlikely to directly affect control, an objective outcome.  It may 
affect control indirectly by promoting compliance but this would occur in practice. 
Generally overstates benefit of GMP. 
Meta-epidemiology suggests various forms 
of unbinding are generally associated with 
overly optimistic effect estimates, 
particularly where outcomes are subjective 
(Savovic et al., 2010). Analyses for separate 
sources of unbinding are not available. 
Blinding of 
outcome 
assessment (4) 
Low Personnel aware of allocations may measure outcomes in a manner that introduces bias. 
This is not important as objective measures like plasma phe are far less subject to 
manipulation, misinterpretation and bias than subjective measures such as pain.  
Generally overstates benefit of GMP. 
As above. Bias is less likely and of smaller 
magnitude with objective measures like phe. 
Incomplete 
outcome  
data (5) 
High Systematic differences between conditions in the number of exclusions or withdrawals  
can bias results if the reasons underpinning them relate to prognostic factors/ outcomes 
and  they are handled improperly.  E.g. patients disproportionately withdrawing from the 
GMP condition as they perceive no benefit or are struggling to comply may overstate 
GMPs benefit if their data are excluded, as good responders will be over-represented in 
analyses (Higgins et al., 2017; CRD, 2008). 
Varies. 
Depends entirely on the extent of 
withdrawals/ exclusions, when they 
occurred, their distribution between 
conditions, the underlying reasons and how 
incomplete data is handled. 
Selective 
outcome 
reporting (6) 
High Selectively publishing supportive findings e.g. those attaining statistical significance or 
supportive sub-sets of data is common and can bias results as non-supportive findings are 
equally important (Dwan, Gamble, Williamson & Kirkham, 2013). The review contains 
many non-randomised studies which are inherently at risk of selective outcome reporting 
as they cannot be checked against protocols, which are not required (Higgins et al.,, 2017). 
Generally overstates benefit of GMP. 
(Dwan, Gamble, Williamson & Kirkham, 
2013). 
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Table 2b: Identification of important quality domains (continued). 
Domain Importance Explanation Likely direction and magnitude of bias 
Carryover in 
within-subject 
designs (7) 
Low Carryover is a form of bias unique to serial, within-subjects designs caused by the effects of 
earlier treatments persisting into periods when subsequent treatments are administered 
and causing confounding  (Higgins et al., 2011). Statistical tests for carryover are 
underpowered so this review assumes carryover is not present unless studies provide 
reasons to expect it (Mills et al., 2000). Barring these, carryover is unlikely as PKU is a 
stable, chronic condition that cannot spontaneously improve or deteriorate and protein 
substitutes have short-lived effects upon plasma phe that rapidly reverse upon cessation.  
Generally overstates benefit of GMP. 
Protein substitutes lower plasma phe so 
inadvertently combining the effects of two 
would likely improve control. 
Influence of 
funding source 
(8) 
High Funding providers or personnel with vested interests in the outcomes of studies may 
introduce bias,  for example by permitting only selected results to be published. However, 
industry funding does not necessarily introduce bias so specific evidence of bias is needed. 
Generally overstates benefit of GMP. 
 
Validity & 
reliability of 
Outcome 
Assessment (9) 
High 
 
If invalid and unreliable methods are used to measure or compare outcomes, changes 
attributed to the intervention or comparator may be partly attributable to measurement 
error. In this instance the difference between most modern methods are inconsequential  
but dried blood spots analysed by tandem MS recover 8-28% less phe than criterion 
methods  and semi-quantitative methods like the original Guthrie Assay are sometimes 
used (van Wegberg et al., 2017). 
Varies. 
Depends entirely on the extent and 
distribution of errors. 
External 
validity 
of study (10) 
High Various factors can reduce the generalisability of findings to clinical practice (a) Some 
studies use weak comparators by comparing powdered formula requiring weighing & 
preparation to food-like GMP products, which may exaggerate compliance/ control 
differences as ready-to-drink formulas are increasingly used (b) Inpatient studies do not 
recreate practice and all report 100% compliance, suggesting Hawthorne effects mask 
important compliance differences (c) some studies selectively recruit patients that like 
GMP & allow them to self-select from a wide range of foods,  something unlikely to occur 
in practice. (d) some studies use preliminary forms of GMP poorly representing commercial 
products e.g. by lacking LNAA or containing too much phe.  
n/a. Influences external validity. 
Strictly speaking, external validity depends 
on the scenario findings are applied to. 
However weak comparators, inpatient 
studies and selective recruitment are likely 
to overstate benefit. Using preliminary 
forms of GMP is likely to understate benefit 
as LNNA promote control and additional phe 
impairs it. 
Sample size 
and statistical 
analyses  (11) 
High  Quantitative meta-analyses attribute more importance to studies with larger samples as 
these increase power & precision by better accounting for variation between subjects and 
reducing the possibility of chance explaining findings. Narrative analyses do not unless 
explicit attempts are made to do so.  The appropriateness of statistical analyses also 
influence how much weight should be attached to findings. 
n/a. Influences precision and power. 
Small samples and wide confidence intervals 
reduce the confidence that can be placed in 
findings as chance or random error may 
explain them. 
Other concerns 
RE bias & 
quality (12) 
High A catchall for threats to validity from design limitations, sources of bias or confounding not 
noted elsewhere. Examples include claims that the study is fraudulent and study-specific 
design limitations like recall bias in retrospective designs.   
Varies. 
Depends on form of bias or limitations 
identified. 
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Table 3: Comparison of effect estimates and design quality: adult studies. 
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Ney et 
al., 
(2016) 
30 GMP: 62 ± 40 increase (non-sig) 
AA: 85 ± 40 decrease (sig) 
GMP: 147± 39 higher (p< 0.05) 
✘ 
Slightly 
Worse (10%) 
Low 
Risk 
Low 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
Low 
Risk 
Low 
Risk 75 
 
89 
----------------------------------------------------------------------------------------Higher quality study above. Lower quality studies below---------------------------------------------------------------------------- 
van 
Calcar 
(2009) 
11 GMP: 676 ± 92  
AA: 619 ± 82  (postprandial) 
No sig difference (p >0.05) 
✔ 
Equivalent 
High 
Risk 
High 
Risk 
High 
Risk 
High 
Risk  
Low 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
Low 
Risk 
Low 
Risk 50 
 
56 
Ahring 
et al., 
(2018) 
8 
(6)* 
Comparing drinks 3 & 4* at  
15 to 240 mins (postprandial) 
No sig differences (p >0.05)  
✔ 
Equivalent  
Low 
Risk 
Uncl 
Risk 
High 
Risk 
High  
Risk   
Low 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk  
Low 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 50 
 
56 
Ney et 
al., 
(2009) 
1 GMP: 667 ± 24   
AA: 736 ± 13    
GMP: 10% lower (p <0.05) 
✔✔ 
Slightly 
Better (10%) 
High 
Risk 
High 
Risk 
High 
Risk 
High  
Risk 
Low 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
High 
Risk  
Low 
Risk 42 
 
44 
La Clair 
et al., 
(2009) 
4 GMP: 400 ± 200  
AA: 400 ± 300 (mean ± SD) 
No sig difference (p >0.05) 
✔ 
Equivalent 
High 
Risk 
High 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 33 
 
33 
Pinto 
et al., 
(2017) 
11 GMP: 521 ± 139 
AA: 545 ± 133  (mean ± SD)  
No sig difference (p >0.05) 
✔ 
Equivalent 
 
High 
Risk 
High 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
Low 
Risk 
High 
Risk 
High 
Risk 33 
 
33 
Abbreviations: Uncl = unclear, SE = standard error. *only 6 subjects participated in the comparison of interest: Complete GMP vs AA with identical composition, minus phe 
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Table 4: Compliance during GMP treatment in adults. 
Study Compliance with protein substitute  
prescriptions (overall and frequency) 
Compliance with other dietary 
requirements. 
Where valid & reliable 
instruments used? 
Was compliance clearly improved in 
the GMP condition? 
Ney et al., 
(2016) 
 
Overall consumption: (a) No significant 
difference reported in medical food logs:  
Lower than prescriptions by ~10 g PE / 
kg BM /d in both conditions 
(b) more objective plasma threonine 
measurements detected 6 patients 
complying poorly with GMP (no 
equivalent measure for formula) 
Frequency of consumption: No different 
overall. Improvement noted for GMP in 
a sub-analysis comparing only patients 
receiving GMP & formula second. 
Dietary phe intake increased 
significantly  (p = 0.0259) in the 
GMP condition (by 88 ± 6 mg Phe/d) 
despite the diets being designed to 
contain equal phe content, as 
subjects did not remove dietary phe 
to accommodate the additional phe 
introduced by GMP as required. 
Overall: Yes. 
Protein subs: Daily logs & 
plasma threonine (objective 
measure) 
Diet: Food diaries for the 
last 3 days of each 3 week 
each condition. Some 
estimated, some weighed. 
Eact numbers estimated and 
weighed unclear. 
No. Compliance with protein 
substitutes was either equivalent or 
worse (despite a sub-analysis reporting 
improved frequency for GMP when 
comparing only patients receiving 
GMP and formula second, which has 
no logical basis). 
 
Dietary compliance was worse in the 
GMP condition as patients did not 
compensate for the additional phe 
introduced by GMP as required. 
Ney et al., 
(2009) 
Overall consumption: No significant 
difference between conditions. 
Frequency of consumption: Greater for 
GMP (3 times per day) than AA (once 
per day). Attributed to better taste. 
No differences noted between 
conditions (emailed author to 
confirm). 
Overall: Yes. 
Protein subs: Daily logs.  
Diet: Estimated food diaries 
for last 3 days of each 
condition & weekly phone 
interviews. 
Yes. Greater frequency of ingestion 
was noted for GMP (3 times per day) 
than formula (once per day). The sole 
patient  consumed all their daily 
formula prescription at once due to 
get rid of it due to its poor taste 
van Calcar 
et al., (2009) 
100% compliance in both conditions. For 
days 1-2 of formula condition, weighed 
food was provided and uneaten food 
returned. Other days as inpatients. 
100% compliance in both conditions, 
as previous column.  
Apparently, though 
monitoring methods 
unclear.  
n/a. The inpatient setting prevented 
compliance differences from 
occurring.  
Ahring et 
al., (2018) 
100% compliance in both conditions. 
Single meal provided in laboratory. 
100% compliance in both conditions. 
Single meal provided in laboratory. 
See previous column. n/a. The inpatient setting prevented 
compliance differences occurring. 
La Clair et 
al., (2009) 
Unclear. Clarification requested via 
email but no response received. 
Unclear. Clarification requested but 
no response received. 
Unclear. See previous 
columns. 
n/a. Compliance levels not reported 
and clarification not received via email. 
Pinto et al., 
(2017) 
Compliance with protein substitutes was 
not monitored (emailed author). 
Compliance with dietary advice was 
not monitored (emailed author). 
Compliance not monitored. n/a. Compliance was not monitored 
(emailed author to confirm). 
Abbreviations: PE = protein equivalent. BM = body mass. D = day.  Subs = protein substitutes. 
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Table 5: Characteristics of included child studies. 
 
Study Methods Participants Intervention & comparator Outcomes Notes 
Zaki et al., 
(2016) 
Non-randomised feasibility study 
with a self-controlled, within-
subjects design. n= 10 children  
underwent 9 weeks GMP treatment 
(50% GMP, 50% formula) then 9 
weeks usual treatment (100% 
formula, 0% GMP). Data is presented 
for final 7 weeks to avoid carryover. 
A preliminary form of GMP cheese-
spread was developed and pilot-
tested in the study.  
Number: 10 
Age: 4 – 16 (median  7) 
Population: Clinic 
patients 
Severity: all Classical 
History: Compliant for 
2m before study.  
Setting:  Outpatients 
Country: Egypt 
GMP format: Spread made from 
commercial GMP, butter & salt  
Phe content: 4.8mg / g PE (high!)  
LNAA content: Unclear 
Nutritionally complete: unclear 
Commercial product: No. 
% formula replaced: 50% 
Same GMP in every patient: yes 
AA format: Unknown 
Same AA in all subjects: unknown 
Phe measured weekly for 7 
weeks. Analysis via “tandem 
mass spectrometry and 
nonderivatised amino acid/ 
acyl-carnitine kits” 
 
Timing of tests, whether they 
were fasting and whether blood 
spots or blood draws were used 
are all unknown.  
Many aspects of design  
remain unclear as published 
report lacked detail and no 
response  was received to 
request for clarification. 
Daly et al., 
(2017) 
Non-randomised, prospective, pilot 
study with parallel design. Compares 
control over 6 months between n=9 
children remaining on 100% formula 
and n=12 (different) children 
replacing it with GMP. In 7 subjects, 
the amount of formula replaced by 
GMP had to be reduced to prevent 
control loss on ethical grounds. The 
amount of formula safely 
replaceable by GMP was 30%  - 100% 
(median 50%). Again, a preliminary 
form of GMP was pilot-tested. 
No: 21 (1 exclusion)  
Age: 6–16  (median 11) 
Population: Clinic 
patients 
Severity: Varied. See 
table 2 
History: 70% of past 2y 
monitoring optimal. 
Setting:  Outpatients 
Country: England 
GMP format: Unknown  
Phe content: 1.5mg / g PE  
LNAA content:  Low compared to 
formula and GMP used elsewhere. AA 
profile met WHO 2007 PKU guidelines. 
Nutritionally complete: Yes 
Commercial product: No. 
% formula replaced: 30 – 100%. 
Same GMP in every patient: no 
AA format: Mainly liquid pouches 
Same AA in all subjects: no 
Dried blood spots collected 
once per week after overnight 
fast. Sent to lab and analysed 
via tandem MS. 
 
Above compared to  (a) 
baseline (b) concurrent control 
group (between-subjects 
comparison) (c) retrospective 
clinical data for previous 12M 
(within-subjects comparison) 
No response received to 
request for clarification. 
 
Retrospective, within-subjects 
comparison used as between-
subject comparisons do not 
allow for differences in 
tolerance, severity etc. but a 
concurrent control group was 
present. 
 
 y = year, m = month, WHO = World Health Organisation. NB phe content refers to content of raw GMP (unless otherwise stated). Content of complete products or meals varie 
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Table 6: Characteristics of ongoing child studies. 
Study Methods Participants Intervention & comparator Outcomes Reason not included 
Daly, 
Chahal, 
Evans & 
MacDonald 
(2016) 
 
 
Continuation of the study described 
in Daly et al., (2017) which was a 
pilot for an ongoing 3 year study. 
Originally, control loss necessitated 
individual-level adjustments of the 
amount of formula replaced by GMP 
and as little as 30% was safely 
replaceable in some cases (but an 
average of 50%). 
In response, GMP was modified as 
below and the study continued using 
the same design and subjects. 
(a) extra tyrosine for 4 months. 
(b) extra LNAA for 5 months. 
Results discussed in discussion. 
No: 21 (1 exclusion)  
Age: 6–16  (median 11) 
Population: Clinic 
patients 
Severity: Varied. See 
table 2 
History: 70% of past 2y 
monitoring optimal. 
Setting:  Outpatients 
Country: England  
GMP format: Unknown  
Phe content: 1.5mg / g PE  
LNAA content: Base GMP in Daly et al., 
described above. Drinks b in this 
extension contained extra LNAA. 
Quantity unclear (not published). 
Nutritionally complete: yes.  
Commercial product: No. 
% formula replaced: varied. Specifics 
unknown (not published)  
Exchanges removed?  Unknown. 
Same GMP in every patient: no 
AA format: mainly liquid pouches 
Same AA in all subjects: no.  
Presumably the same as Daly et 
al., (2017) above, as this is an 
extension of the same study. 
However this not known as the 
extension is not yet published. 
Could not be included as full 
text  and detailed findings 
unavailable so quality 
evaluation was impossible.  
 
Paper outlining 12 month 
findings currently undergoing 
publication. 
 
Study initially identified via 
conference abstract (Daly et 
al., 2016). Additional details 
obtained via email 
correspondence with author. 
 
Table 7: Characteristics of excluded child studies. 
Study Methods Participants Intervention & comparator Outcomes Reasons for exclusion 
Abdel- 
Salam & 
Effat 
(2010) 
Non-randomised study comparing 
control after 3 days GMP treatment 
to baseline. What baseline treatment 
consisted of is unclear. Control data 
is presented for three groups but the 
number of patients in each and their 
ages are also unclear. 
Number: 10 or 30: 
unclear 
Age: “infants to adults” 
range unclear 
Population: Hospital 
patients 
Severity: Unknown 
History: Unknown  
Setting:  Unknown 
Country: Egypt 
GMP format: Novel drink. Emulsion of 
corn oil and GMP in milk permeate.  
Phe content: Unknown. Finished Drink 
contained 12mg/ 100ml 
LNAA content: Unknown 
Nutritionally complete: Unknown.  
Commercial product: No. 
% formula replaced: Unknown.  
Exchanges removed?  Unknown. 
Same GMP in every patient: yes 
AA format: Unknown.  
Same AA in all subjects: Unknown.  
Phe measured at baseline and 
after 3 days (study-end). 
 
Conditions control data was 
collected under and method of 
analysis unclear.  Method may 
be original Guthrie method 
which is only semi-quantitative. 
(a) No control condition (as 
required in protocol). Control 
following three days of GMP 
compared to baseline.  
(b) Translated from Egyptian 
unclearly and vague, making it 
difficult to understand even 
basic aspects of the design. 
No response to a request for 
clarification was received.  
(c) Unrealistically large control 
improvements were reported 
(30- 80% over 3 days). 
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Table 8: Comparison of effect estimates and design quality: child studies. 
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-----------------------------------------------------------------------------------Lower quality studies below. No higher quality studies were located-------------------------------------------------------------------- 
Daly et 
al., 
(2017) 
Varied. 
30 –  
100% 
(n = 22) 
GMP: 42 increase (sig) 
AA: 45 decrease (non sig)  
(Median change vs retro data) 
GMP: sig higher (p <0.05)  
✘ 
Slightly 
Worse * 
  
High 
Risk 
High 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
High 
Risk 
High 
Risk 
High 
Risk 
Low 
Risk 
33 33 
Zaki et 
al., 
(2016) 
50% 
(n = 10) 
GMP: 376 (167 – 551)  
AA: 490 (289 – 597) 
Using: Median (interquartile) 
No sig difference (p >0.05) 
✔ 
Equivalent High 
Risk 
High 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Uncl 
Risk 
Low 
Risk 
Low 
Risk 
Uncl 
Risk 
High 
Risk 
Uncl 
Risk 
Uncl 
Risk 
17 
 
11 
 
*average difference between conditions is smaller than that observed by Zaki et al., (2016) but attained statistical significance due to larger 
sample and increased power. 
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Table 9: Compliance during GMP treatment in children. 
Study Compliance with protein substitute  
prescriptions (overall and frequency) 
Compliance with other dietary 
requirements. 
Where valid & reliable 
instruments used? 
Was compliance clearly improved in 
the GMP condition?  
Zaki et al., 
(2016) 
Unclear. Clarification requested via 
email but no response received. 
Unclear. Clarification requested but 
no response received. 
Unclear. See previous 
columns. 
Unclear Compliance not reported and 
clarification not received via email. 
Daly et al., 
(2017) 
 
Unclear. 
Compliance levels and frequency of 
intake are not reported and clarification 
was not received via email. The report 
mentions monitoring remaining stocks 
of protein substitutes during monthly 
home visits, but also identifies “failure 
to complete prescribed dose of protein 
substitute” as a possible confounder 
No significant difference between 
conditions.. 
~50% more protein than 
recommended was consumed in 
both groups (5g extra in GMP, 4.5g 
extra in AA)  
 
Overall: No (subjectively) 
Protein subs: Monthly 
home visits. 
Diet: 3-day weighed food 
diaries during the first and 
final week of each ~6 month 
condition & monthly home 
visits but authors note 
dietary non-compliance as a 
possible confounder 
Unclear. No differences between 
conditions are reported. However, 
dietary compliance was monitored in 
detail only in the first and last weeks of 
~6 month treatment periods and 
compliance levels with protein 
substitutes are not reported. The 
authors themselves identify non-
compliance with both aspects as 
potential sources of confounding. 
 
Table 10: Inter-individual variation in responses to GMP (both groups). 
Group Study Effect  (mean difference ± SEM 
between AA and GMP treatment) 
and % of formula replaced by GMP. 
Extent of inter-individual variation (µmol/L) Where any determinants of inter-individual variation 
noted? 
Adults van 
Calcar et 
al., 
(2009) 
No significant difference 
AA: 619 ± 82 µmol/L 
GMP: 676 ± 92 µmol/L  
100% replaced. 
Responses varied from: 
175 µmol/L decrease to 257 µmol/L increase 
No. No consistent associations between the response to 
GMP, sex, genotype, and age were noted (using 
correlations) 
Adults Ney et 
al., 
(2016) 
Significant increase of 147 ± 39 v AA   
(deterioration in control) 
AA: -285 ± 40 µmol/L (sig) 
GMP:  +62 ± 40 µmol/L (non-sig) 
100% replaced 
Phe increased in 18 subjects & decreased in 12. 
Responses varied from:  
~200 decrease to ~400 increase (using 
approximate 10th &  90th percentiles of box and 
whisker plot) 
Yes. ANOVA noted interactions between control changes 
and:  
(a) total phe consumed through diet and GMP  
 (b) Baseline phe concentration 
Suggesting these influence responses. 
Children 
 
Daly et 
al., 
(2017) 
Significant increase of 87 µmol/L  
GMP: 42 increase (sig) 
AA: 45 decrease (non sig)  
30 – 100% replaced 
Variation in responses not noted as % replaced 
was adjusted for ethical reasons if control left 
safe ranges. Amount safely replaceable varied 
from 30- 100% 
No. 
Authors suggest the amount of GMP introduced 
influenced responses & that tolerance influenced the 
amount safely replaceable but did not run correlations. 
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Table 11: Confidence in the body of evidence reviewed (GRADE score). 
 Review of studies involving adults  (16 years old and over) Review of studies involving children  (3 – 16 years old) 
Patients PKU patients (inpatients & outpatients) PKU patients (inpatients & outpatients)  
Outcome Change in plasma phe control Change in plasma phe control 
Intervention GMP based foods GMP based foods 
Comparator Amino-acid formulas (usual treatments, which varied) Amino-acid formula (usual treatments, which varied)  
No of patients 63 32 
Follow up 240 minutes to ~12 months 7 weeks to ~6 months 
No of studies 
& designs 
n=6: 2 randomised crossover trials (1 very short duration).  
3 non-randomised studies. 1 self-controlled case report. 
n=2: 2 Non-randomised pilot studies. 
Initial score  Low quality. Evidence mainly from non-randomised studies 
(NRS). 
Low quality. Evidence exclusively from non-randomised 
studies. 
Risk of Bias Minus 1 point.  Several studies susceptible to bias (e.g. 
selective reporting) and/ or confounding  (by diet/ compliance) 
Minus 1 point.  Both studies susceptible to bias (e.g. selective 
reporting) and/ or confounding  (by diet/ compliance) 
Inconsistency No deductions. Results broadly consistent. Inconsistency 
apparently explained by bias/ design quality.  
No deductions. Average amount of formula replaced identical 
(50%) but different approaches used. 
Indirectness  Minus 1 point. One study selectively recruited patients liking 
the intervention and several used weak comparators. 
Minus 1 point. The preliminary forms of GMP used differ from 
commercial products in organoleptic, LNAA and phe content. 
Imprecision Minus 1 point. CIs unavailable but 4 of 6 studies have too few 
subjects to provide adequate power so likely to lack precision. 
No deductions. CIs unavailable but samples seem large enough 
to provide adequate power, suggesting acceptable precision. 
Publication bias 
(meta-bias) 
Minus 1 point. Evidence mainly from small, industry-linked, 
supportive, NRS. No small, non-supportive studies located. 
Minus 1 point. Studies all NRS which face increased risk of 
publication bias (registrations unnecessary). 
Quality of 
evidence base 
 Very low  
(lowest possible score) 
Very low 
(lowest possible score)  
Conclusion of 
review  
Control is likely to deteriorate by ~10% on average after totally 
replacing formula with GMP but responses may vary. Patients 
may fail to compensate for the additional phe introduced by 
removing exchanges and control may deteriorate in some 
cases. Control and compliance should thus be monitored. 
The very limited data available suggest GMP cannot totally 
replace formula in all children as in adults.  The amount of 
formula safely replicable by GMP varies between individuals 
(~30- 100%) so if GMP is used, control must be monitored 
carefully and the dose adjusted if control leaves safe ranges. 
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4.0: Discussion 
For complete details and evaluations of studies: tables 1, 3 & 5-8. 
4.1: Objective 1a: effect of GMP on control in light of bias & design quality (adults). 
Analyses contained two RS (Ney et al., 2016; Ahring et al., 2018) and four NRS (others in 
table 3). In such instances, Cochrane recommend separately analysing study types to avoid 
attaching undue weight to NRS (Reeves et al., 2011). The analysis instead separated studies 
by design quality (table 3) as one RS (Ahring et al., 2018) was at risk of inadequate 
randomisation and had other major limitations (below). 
 
4.1.1: Objective 1a: Primary analysis (high quality studies). 
Objective 1a  was primarily addressed through one study (Ney et al., 2016). This randomised 
crossover compared 3 weeks treatment with 100% GMP and formula among 30 outpatients. 
Whilst its abstract reports equivalent control on GMP to baseline and the preceding 
narrative review accepted this, control was highly significantly worse than the formula 
comparator (p< 0.0008) by ~10% or +147 ± 39 µmol/L (mean ± SE). This change represents 
~30% of ESPKU recommended ranges: 120 – 600 µmol/L (van Wegberg et al., 2017) 
suggesting it could compromise control in some cases. Furthermore, responses varied 
between individuals: control improved in 40% of subjects (by upto ~200 µmol/L) but 
worsened in 60% (by upto ~400 µmol/L). None-equivalent control may relate to compliance 
difficulties during GMP treatment as every subject failed to remove exchanges to 
compensate for GMPs phe content (as required) and an additional 88mg ± 6 phe was 
consumed. The self-reported dietary assessments used are error-prone but subjects 
consciously misreporting generally do so in desirable directions (Macdiardmid & Blundell et 
al., 1998; Prince et al., 1997) so patients would not be expected to so consistently misreport 
69 
 
overconsuming protein, suggesting reported intakes are accurate. An optimistic conclusion 
is that control would be better or even equivalent (on average) if compensation occurred. 
However, this was not demonstrated and difficulties compensating are concerning. Risk of 
most bias forms considered important in this context (table 2a) was low (table 3) and power 
was ample but one limitation may overstate GMPs benefit. The study exclusively recruited 
participants finding GMP acceptable, then permitted self-selection of GMP foods from a 
wide variety. This occurred before randomisation so threatens external (not internal) 
validity, something that depends on the scenario findings are applied to (CRD, 2009). 
However, most patients are unlikely to pre-sample GMP and select their preferred format 
from so wide a range, suggesting findings may overstate benefit when applied to the typical 
treatment scenario.  
 
4.1.2: Objective 1a: Secondary analysis in (low quality studies) 
Lower-quality studies generally reported equivalent control (table 3) but were susceptible to 
confounding and several bias forms likely to overstate GMPs benefit suggesting these more 
optimistic findings are misleading. Their findings were thus largely disregarded, though 
studies are evaluated briefly. In all five, randomisation was inadequate (Ahring et al., 2018) 
or absent (others). Prognostic imbalance is unlikely as all had self-controlled designs but 
preferential assignment to treatment periods could occur and usually overstates benefit 
(Higgins et al., 2011; Savovic et al., 2012). None used prospective protocols so selective 
outcome reporting may have occurred and generally overstates benefit (Dwan et al., 2013). 
Also, poor reporting left many design details unclear and clarification was only received for 
Ney et al., (2009) & van Calcar et al., (2009a). Given the low quality of studies, analyses 
considered poor reporting analogous to poor conduct, the most conservative approach. 
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Inpatient studies lack ecological validity as treatment is generally provided to outpatients 
and they artificially promote compliance. However, by better controlling for compliance 
differences they could directly describe GMP’s impact on control. The two reviewed (Ahring 
et al., 2018 & van Calcar et al., 2009a) reported equivalent control alongside 100% 
compliance, supporting the above suggestion that broadly equivalent control would occur 
(on average) if compensation occured. However, in addition to the limitations noted above, 
both monitored control exclusively in the postprandial condition over unrealistically  short 
timeframes (2 hours in Ahring et al., (2018)  & 2 days in van Calcar et al., (2009a)) when 
treatment is lifelong and fasting control is equally important. Also, the comparison of 
interest in Ahring et al., (2018) (complete GMP formulation vs formula with an identical AA 
composition, minus phe) involved 6 patients so lacked power. Therefore, little confidence 
can be placed in these findings. Future inpatient studies should use randomisation, power 
calculations, prospective protocols, Consort guidance to clarify reporting, sufficient 
durations (at least three days per condition) and measure fasting and postprandial plasma 
phe. 
The remaining three studies were even more limited (table 3). Only a case study (Ney et al., 
2009) reported improved control (~10%) but this means little as the participant could be an 
outlier and the effect may be due to chance. The final two studies reported equivalent 
control but compliance formed an uncontrolled confounding variable as it was either not 
reported (LaClair et al., 2009) or monitored inadequately (Pinto et al., 2017). Pinto and 
colleagues also monitored control monthly, overlooking important fluctuations within 
months. The latter study was the only to partially replace formula in adults (27 - 100%). This 
reduces the need to remove dietary exchanges and may (theoretically) improve compliance/ 
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control where this proves challenging but the study could not demonstrate the safety/ 
utility of the approach given its limitations. 
 
4.1.3: Objective 1a: Summary & suggestions for research and practice (adults). 
To minimise bias, conclusions are based on a single high-quality study (Ney et al., 2016). It 
selectively recruited patients finding GMP acceptable and allowed patients to select from 
many GMP foods, suggesting findings may prove optimistic in less ideal treatment scenarios. 
However, it was otherwise well-designed suggesting its findings (slightly inferior control on 
average following 100% replacement, partly relating to difficulties removing exchanges but 
inter-individual variation in responses) are valid. Better control would be expected if 
exchanges were removed to accommodate the phe in GMP. However, as only one high 
quality study was reviewed, these conclusions should be considered tentative until 
confirmed in similarly well-designed studies that better recreate practice by using less 
selective recruitment. Were several sufficiently strong, homogenous studies conducted,  
meta-analyses could confirm GMPs effect on control with increased power. However the 
lack of upcoming studies suggests this is unlikely, particularly as formula (which is 
universally recommended) is yet to amass such evidence (Yi, & Singh, 2015). Practioners 
prescribing GMP should expect slightly worse control on average but monitor phe closely as 
responses vary. As patients may struggle to remove exchanges, compliance should be 
monitored and dietary counselling offered if required. Partial replacement reduces the 
requirement to remove exchanges and could theoretically improve compliance/ control but 
the safety/ efficacy of the approach is yet to be demonstrated. 
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4.2: Objective 2a: Effect of GMP upon compliance (adults). 
Compliance has three components. Firstly, consuming prescribed quantities of protein 
substitute (Macdonald et al., 2006; Duran, Rohr, Slonim, Guttler & Levy, 1999). Secondly, 
distributing this over 3-4 meals (Monch et al., 1996). Thirdly, consuming the correct 
quantities of dietary protein (and phe) and energy (to avoid catabolism which increases 
plasma phe). Regarding the quantity of protein substitute, no studies reported differences 
between conditions using self-reported logs (table 4). Ney et al., (2016) reported six subjects 
consuming insufficient GMP using objective plasma threonine measurements, raising 
concerns and suggesting protein logs overstate compliance, but inferior compliance was not 
objectively demonstrated as no objective measure of formula consumption exists. 
Regarding distribution of protein substitutes, the sole participant in Ney et al., (2009) 
reported improvements with GMP (three times per day vs once) citing its taste but may 
have been an outlier and the study used a weak comparator by comparing self-selected, 
ready-to-eat GMP to a powdered formula requiring preparation which may exaggerate 
compliance differences as formula is available in better-tasting, ready-to-drink formats 
(Macdonald et al., 2004; Prince et al., 1997). Ney et al., (2016) addressed this shortcoming in 
the strongest study and also reported improved distribution in the abstract but this is 
questionable as distribution only improved during a sub-analysis comparing patients 
receiving GMP and formula second. This distinction has no logical basis, the sub-analysis was 
not planned a-priori and distribution did not improve overall.  Regarding dietary compliance, 
Ney and colleagues reported worse compliance on GMP as dietary protein was not removed 
(discussed previously). Overall, and contrary to expectations, the review found no reliable 
evidence of compliance improving on GMP-based therapeutic diets and some evidence that 
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removing exchanges may prove difficult. Future outpatient studies should clarify GMPs 
effect upon compliance using valid and reliable methods like the daily protein logs, plasma 
threonine monitoring and three-day weighed food diaries (per week) used by Ney et al., 
(2016). However, self-reported methods of assessing protein substitute (Prince et al., 1997) 
and dietary intake (Macdiardmid & Blundell et al., 1998) are error-prone, plasma threonine 
does not permit between-condition comparisons and inpatient studies risk introducing 
Hawthorne effects, so GMPs effect on compliance is difficult to describe accurately.  
 
4.3.1: Objective 1b: effect of GMP on control in light of bias & design quality (Children). 
As children require more protein (per kg BM) than adults for growth (WHO, 2007) but 
tolerate less phe (van Wegberg et al., 2017) formula comprises more of their diets. 100% 
replacement of formula with GMP thus appears impossible in some children as excessive 
phe is introduced and insufficient protein is consumed to remove in compensation. The two 
child studies reviewed (table 5) instead partially replaced formula with GMP. Zaki et al., 
(2016) compared treatment with 50% GMP, 50% formula to 100% formula and noted 
equivalent control as the 114 µmol/ L improvement in average control observed failed to 
obtain statistical significance.  Daly et al., (2017) provided 12 children with GMP and a 
parrallel control group of 9 different children with 100% formula, monitored control for 6 
months prospectively, compared this to 12 months historical control data (within-subjects) 
then compared changes between groups (between-subjects). Average control was 
significantly worse during GMP treatment, by 87 µmol/ L. However, both studies used 
different approaches. Zaki and colleagues replaced 50% of formula in all subjects whilst Daly 
and colleagues adjusted the proportion replaced on an individual basis if control left safe 
ranges for ethical reasons. The amount safely replaceable varied from 30 – 100% and whilst 
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it is likely similar inter-individual variation was noted by Zaki & colleagues (but manifested 
as variation in responses), individual patient data and variance data were not provided. 
What mediates this variation is unclear, though more GMP is likely to be replaceable in 
higher-tolerance patients. Findings suggest the amount of formula safely replaceable by 
GMP varies between children but this conclusion must considered extremely tentative as 
only two studies underpin it which have severe limitations. 
 
One limitation is likely to understate GMPs benefit: the preliminary GMP formulations both 
studies used. Zaki & colleagues produced a spread from GMP much higher in phe (4.8 mg/ g 
Protein) than commercial products such as ‘Glytactin’ (1.8 mg/ g Protein) used by Ney et al., 
(2016), which must have impaired control. GMP lacks certain LNAA and requires 
supplementation to form a complete AA source. Daly and colleagues used GMP with an 
LNAA content meeting WHO (2007) requirements, less than Glytactin used by the Ney 
Group  which contains 150% of the USA RDI for Tyrosine & 130% for other limiting LNAA  
(Van Calcar & Ney, 2012). This is likely to reduce the amount safely usable as LNAA appear 
to improve control by competitively inhibiting intestinal phe uptake (Matalon et al., 2006; 
2007). Preliminary findings from a continuation of Daly’s study (Daly et al., 2016) support 
this suggestion (table 6). Using the same design and subjects, the LNAA content of GMP was 
increased for five months and the average amount safely replaceable increased from 50% to 
75%. This suggests more beneficial responses would occur with commercial GMP products 
lower in phe and higher in LNAA but this requires confirmation as the continuation of Daly & 
colleagues’ study awaits publication so its details remain unclear and both studies have 
several limitations (below).  
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Neither published a protocol so selective outcome reporting, which generally overstates 
benefit, cannot be excluded (Dwan et al., 2013). Both lacked randomisation so selection bias 
cannot be excluded particularly in Daly et al., (2017) as concurrent groups selected 
treatments. Both studies also collected data under poorly controlled (clinical) conditions, 
risking confounding, particularly via differential compliance. Zaki & colleagues did not report 
monitoring compliance and Daly & colleagues identified compliance as a possible 
confounder since monitoring was inadequate (table 9). Both were also susceptible to 
measurement errors. Zaki and colleagues omitted important details regarding control 
measurements which affect findings such as time of collection, whether blood samples were 
fasting or postprandial and whether dried blood spots or blood draws were used. It is even 
unclear which analysis method was used and one of those mentioned appears semi-
quantitative (nonderivatised amino acid/acyl-carnitine kits) calling the validity of findings 
into question. Daly and colleagues used DBS for between-subject comparisons. These 
recover 8-26% less phe than criterion methods but the error varies between individuals 
(Stroup et al, 2016) making such comparisons problematic. Further, between-subjects 
comparisons do not allow for differences in tolerance & baseline control, explaining why 
other studies use within-subjects designs.  
 
4.3.2: Objective 1b: Summary & suggestions for research and practice (children). 
Reviewed studies suggest the amount of formula safely replaceable by GMP without 
dangerous control loss varies between children, from ~30 – 100%. What mediates this 
variation is unclear though tolerance appears important (logically). As preliminary forms of 
GMP high in phe and low in LNAA were used in reviewed studies, more beneficial responses 
may occur with commercial GMP (e.g. Glytactin). However, conclusions are based on only 
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two studies susceptible to confounding, measurement errors and multiple forms of bias 
likely to overstate benefit (table 8) so conclusions should be considered extremely tentative 
until confirmed in stronger designs. These may be ethically required to adjust GMP doses 
individually like Daly and colleagues but should publish IPD and otherwise employ a 
randomised crossover design resembling Ney et al., (2016). This would prevent selection 
bias, permit within-subject comparisons and preclude the need for retrospective data. 
CONSORT compliance would ensure clear reporting and a prospective protocol would 
prevent selective reporting. Power calculations and oversampling would ensure adequate 
power and a validated plasma phe analysis method should be used, e.g. DBS analysed via 
tandem MS, which is convenient for outpatients as DBS collected at home can be posted. 
Ecological validity should be ensured by using GMP available in clinic. As residual phe 
content limits GMP’s utility in children most, improved purification techniques should be 
investigated.  Practioners choosing to prescribe GMP in children must be aware of the risks, 
monitor control carefully and adjust doses as the amount of formula safely replaceable 
varies. Whilst it is unclear what mediates this variation, less GMP is likely to be permissible 
in lower tolerance patients. GMP products high in LNAA and low in phe (e.g. Glytactin) 
should be selected as these appear to improve control and permit more replacement. 
Compliance should be monitored and counselling offered where needed. 
 
4.4: Objective 2b: Effect of GMP upon compliance (children). 
The review was unable to clarify GMPs effect upon compliance in children (table 9). Zaki & 
colleagues did not report monitoring compliance and Daly and colleagues identified non-
compliance as an uncontrolled confounding variable because assessment methods were 
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inadequate. Future studies should rectify this using methods described for adults alongside 
the design features described previously.  
4.5: Limitations of review 
Inter-individual variation in responses occurred in adults (table 10) and in the amount of 
GMP permissible in children (30% - 100%)  (Daly et al., 2017). However, the range of 
probable responses cannot be predicted with any confidence as only one study reporting 
variances was at low risk of bias (Ney et al., 2016). The review was also unable to identify 
mediators of this variation, which may predict patient responses. If several well-designed, 
homogenous studies published IPD, an IPD meta-analysis could quantify inter-individual 
variation and a meta-regression could identify its determinants (associatively) but this 
appears unlikely given the lack upcoming studies. 
GRADE rates the confidence that can be placed in a review’s conclusions by assessing the 
quality of the entire evidence base reviewed (Guyatt et al., 2011). Both reviews received the 
lowest possible rating (table 11) re-iterating that conclusions are extremely tentative. As the 
adult review was largely based upon a high quality study, this may appear overly critical but 
the decision to be conservative was considered safer. 
 
GRADE also identified that both reviews were at risk of publication bias, despite the search 
strategy including grey literature and registries to prevent this. Language bias cannot be 
excluded as, without translation facilities, only English studies were reviewed. Publication 
bias cannot be excluded as NRS were included in both analyses and prospective registration 
of NRS is rare (Reeves et al., 2011). Both biases generally overstate benefit as supportive 
studies are disproportionately translated and published (Egger et al., 1997; Song et al., 
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2000). Funnel plots and tests for publication bias were impossible as compatible precision 
data was unavailable due to poor reporting (CRD, 2009). Using a subjective approach, both 
analyses predominantly contained small, supportive studies with industrial links and no 
small, unsupportive studies, suggesting publication bias occurred (Guyatt et  al., 2011). 
However such tests are unreliable, particularly in reviews containing few, similarly-sized, 
heterogeneous studies (Lau, Ioannidis, Terrin, Schmid & Olkin, 2006) so whilst publication 
bias appears likely, its presence cannot be confirmed. This may unfairly degrade the adult 
review that was primarily based upon a randomised, registered trial. However, registration 
of randomised trials is not mandatory so publication bias cannot be excluded. Indeed, one 
reviewed randomised study was unregistered (Ahring et al., 2018). 
 
A PRISMA-P compliant protocol was prepared prospectively (appendix 3) but not registered, 
something not required by PRISMA-P (Moher et al., 2009). Resultantly, readers cannot 
exclude the possibility of bias in the review (e.g. changing analyses based on results). 
Different results (statistical heterogeneity) are expected from studies with different designs/ 
populations (between-study heterogeneity). As statistical tests for heterogeneity have 
limitations, a subjective approach was used (Schünemann, Brożek, Guyatt & Oxman, 2013). 
Confidence intervals were unavailable due too poor reporting and whilst ‘point estimates’ 
varied both in magnitude (by 10-20%) and direction in adults, differences were (subjectively) 
attributed to design limitations (table 5). In children, statistical heterogenity was minimal as 
both studies reported (broadly) equivalent control but both used fundamentally different 
approaches making comparisons difficult. Given this, the subjective analyses used and the 
heterogeneous studies the relaxed inclusion criteria permitted, the contribution of 
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heterogeneity (e.g. differences in tolerance, history of control, setting and type of formula/ 
GMP used) to differences in effects cannot be excluded but it (subjectively) appears minimal 
as little statistical heterogeneity went unexplained.   
Some adult studies contained patients under 16 (e.g. van Calcar et al., 2009a) but this is 
unlikely to affect results as examples were rare and all had tolerances comparable to adults. 
Moreover, all but one was over 12 and certain authorities (e.g. ESPKU) recommend 
relaxation of control at 12 rather than 16 (van Wegberg et al., 2017).  
As the review addressed objectives previous reviews had not, findings cannot be compared 
to them. It is instead considered whether the systematic methods used addressed the 
reviews objectives and expanded upon conclusions of the preceding review. The exhaustive 
search methods located three additional adult studies: Laclair et al., (2009), Pinto et al., 
(2017) & Ahring et al., (2018) and the critical approach noted that Ney et al., (2016) 
reported a non-supportive findings, something the narrative review overlooked. In children 
a unique upcoming study was located (Daly et al., 2016) and an uncontrolled study (Abdel-
Salam & Effat, 2010) reporting unrealistically optimistic control improvements that was 
previously reviewed but could have skewed results  was excluded (table 7). The additional 
studies were bias-prone and contributed little to conclusions but this was not apparent 
beforehand; additional randomised trials may have existed. Moreover, authorities agree 
that identifying limitations in existing research and making recommendations for upcoming 
studies are themselves important functions of a systematic review (Schünemann et al., 
2017; CRD, 2009; Moher et al., 2009), functions this review fulfilled.   
The review included NRS, something Cochrane only recommend when randomised studies 
are impractical as misleading conclusions may be drawn due to bias (Reeves et al., 2011). In 
80 
 
adults the high quality study was analysed separately and conclusions based upon it, so 
misleading conclusions due to bias are unlikely.  Given the few existing and upcoming 
studies involving children (none of which are randomised), the suggestion that children 
resist randomisation (Daly et al., 2017), wider difficulties facing PKU research including its 
low prevalence and difficulties applying adult findings to children, the inclusion of NRS 
involving children is defensible. It permitted  important (albeit tentative) observations a 
review excluding NRS would overlook, namely that the amount of formula safely 
replaceable apparently varies between children  and that the LNAA and phe content of GMP 
influence responses. Moreover, the same conclusion a review excluding NRS would draw 
was arrived at: that stronger studies are required. Given the transparent methods used and 
that the abstract stresses conclusions are tentative, conclusions are unlikely to mislead. 
5.0: Conclusions 
The review included six studies involving adults (over 16) but only a single randomised trial 
at low risk of bias (Ney et al., 2016). To minimise bias, conclusions were primarily based 
upon this. It suggests control will deteriorate by ~10% (or 147 µmol/L)  on average if formula 
is totally replaced by GMP, which may prove clinically significant in some cases. However, 
responses varied from an ~200 µmol/ L improvement to an ~400 µmol/ L deterioration. 
Given this variation in responses, the mediators of which remain unidentified, monitoring 
control during treatment appears essential. The deterioration in control observed partly 
related to compliance difficulties as every subject failed to reduce dietary protein intake to 
accommodate the residual phenylalanine in GMP. Better control would be expected if 
dietary protein was removed but difficulties doing so could threaten control, so compliance 
should be monitored and counselling offered where required. The study had one limitation 
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that may overstate benefit: it selectively recruited patients finding GMP acceptable and 
permitted self-selection of GMP foods from a wide variety. Therefore, less beneficial 
responses may occur under less ideal treatment conditions. Contrary to expectations, the 
review found no reliable evidence of compliance improvements during GMP treatment and 
some evidence  of compliance difficulties (aforementioned). However, as conclusions are 
based on a single randomised trial, they are tentative and caution is advised among 
practioners deciding to prescribe GMP to adults until further high quality studies are 
performed to clarify its effect upon control and compliance.  
Two studies involving children (3 – 16) met inclusion criteria.  These suggest GMP cannot 
totally replace formula in all children without plasma phe leaving safe ranges as tolerances 
are lower, formula comprises more of the diet and insufficient exchanges are consumed to 
remove in compensation. The amount safely replaceable appears to vary between children 
from ~30 – 100%. What mediates this variation is unclear though more GMP appears 
permissible in higher-tolerance children. However, both studies had heterogeneous and 
extremely limited designs in which selection bias, selective outcome reporting, 
measurement errors and uncontrolled confounding variables (particularly compliance) may 
have affected findings. Both also pilot-tested incomplete GMP formulations lower in LNAA 
and higher in phe than those used clinically, something likely to reduce effectiveness.  
Therefore, conclusions must be considered extremely tentative until confirmed in well-
controlled randomised trials. Practioners choosing to prescribe GMP in children should 
exercise extreme caution, select products high in LNAA and low in Phe (e.g. Glytactin), 
monitor control and compliance carefully and reduce GMP doses if control leaves safe 
ranges.  
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6.0: Appendix 1: Full search strategy & results. 
Table 12: Database-type resources A. databases & search engines containing published & unpublished literature 
Resource 
searched 
Date 
searched 
Number of 
raw results 
Resource type Types of reports included Approach used (no limits unless specified) 
Pubmed 30/ 04/ 2018 502  Database  Published journals from MEDLINE 
including those awaiting indexing 
& online books 
Terms: Phenylketonurias OR Phenylketonuria OR PKU OR 
"Phenylalanine hydroxylase deficiency" OR "PAH deficiency" OR 
hyperphenylalaninemia AND GMP OR Caseinomacropeptide OR 
Caseinomacropejohnptides OR Glycomacropeptide OR 
Glycomacropeptides OR "Protein substitute" OR "Protein substitutes" 
OR "amino acid formula" OR “phenylalnine free” 
Cochrane 
Library  
(via search 
manager) 
01/ 05/ 2018 386 Database Published &  unpublished RCTs and 
quasi RCTs from MEDLINE, 
EMBASE, registries, hand searches 
of key journals and a specialist IEM 
register. Cochrane & other 
reviews. 
Terms: Phenylketonuria OR PKU OR "Phenylalanine hydroxylase 
deficiency" OR "PAH deficiency" OR hyperphenylalaninemia AND 
Caseinomacropeptide OR Glycomacropeptide OR GMP near/10 pku 
OR GMP near/10 phenylketonuria OR protein near/1 subset* OR 
“amino acid” near/1 formula OR “phenylalnine free” 
Limiters: (a) Cochrane reviews, other reviews, trials & Cochrane 
groups (other groups irrelevant) (b) “title, abstract & keywords”  
CINAHL ( via 
EBSCO host) 
01/ 05/ 2018 280 Database Published papers and magazines  
(that may include unpublished 
abstracts and other leads to 
unpublished papers). Specific to 
allied health professions (dietetics) 
Phenylketonuria OR PKU OR "Phenylalanine hydroxylase deficiency" 
OR "PAH deficiency" OR hyperphenylalaninemia AND GMP OR 
Glycomacropeptide OR Caseinomacropeptide OR "Protein substitute" 
OR "Protein substitutes" OR "amino acid formula" 
Expanders: “apply related words” 
Web of science 
(advanced 
search) 
01/ 05/ 2018 234 Database Published papers, books & 
conference proceedings (an 
important source of potentially 
unpublished studies). Wider 
coverage of subjects to increase 
sensitivity. 
Terms: TS= (Phenylketonuria OR Phenylketonurias OR PKU OR 
Phenylalanine-hydroxylase-deficiency OR PAH-deficiency OR 
hyperphenylalaninemia) AND TS= (Caseinomacropeptide OR 
Caseinomacropeptides OR Glycomacropeptide OR 
Glycomacropeptides OR GMP OR CMP OR "Protein subst*" OR amino-
acid NEAR/5 formula OR PKU NEAR/5 formula OR Phenylketonuria 
NEAR/5 formula OR phenylalnine-free) 
Zetoc 
 
 
 
02/ 05 /2018 72 Database Published papers and conference 
proceedings (an important source 
of potentially unpublished papers). 
Approach: The search facility has no support for Bolean operators 
and automatically links terms with AND.  This was ‘worked around’ by 
separately searching all fields for: 
1. “PKU AND GMP”  2. “Phenylketonuria AND GMP”  3. “PKU AND 
glycomacropeptide” 4. “Phenylketonuria AND Glycomacropeptide”.  
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Resource 
searched 
Date 
searched 
Number of 
raw results 
Resource type Types of reports included Approach used (no limits unless specified) 
Google Scholar 03/ 05/ 2018 502 Internet search 
engine 
Published papers, conference 
proceedings/ abstracts & 
dissertations/ theses. Crawls sites 
conventional databases may miss. 
Approach: As search facilities lack advanced features searches 
generate many irrelevant results & these must be added to reference 
management software individually. To restrict searches & make 
results manageable, a single search was performed.  
Terms: “phenylketonuria AND glycomacropeptide” 
 
Table 13: Database-type resources B. Databases & search engines specific to unpublished literature. 
Resource 
searched 
Date 
searched 
Number of 
raw results 
Resource type Types of reports included Approach used (no limits unless specified) 
Open Grey 
(previously 
OpenSIGLE) 
03/ 05/ 2018 23 European Grey 
literature 
database 
Research reports, doctoral 
dissertations, conference papers, 
official papers & other grey 
literature. 
Terms: Phenylketonuria OR PKU OR glycomacropeptide OR GMP 
NEAR PKU OR GMP NEAR phenylketonuria 
 
  
New York 
Academy of 
Medicine  
04/ 05 /2018 0 Grey literature 
specific 
database 
Medical grey literature. Updates 
ceased in Jan 2017 but 1999 – 
2017 is still searchable. 
Approach: Used terms of increasing sensitivity. No results found for 
any permutation of either GMP or phenylketonuria. 
Canadian 
Research 
Information 
system 
04/ 05/ 2018 15 Database of 
research 
funding 
allocations 
Studies that Canadian research 
funding was awarded to (potential 
source of published or unpublished 
literature) 
Approach: Separate searches for PKU, Phenylketonuria  & 
Glycomacropeptide. 
Proquest 
Dissertations & 
Theses  
04/ 05/ 2018 242 Database of 
dissertations & 
theses 
Masters theses & doctoral 
dissertations 
Approach: (Phenylketonuria OR PKU OR "Phenylalanine hydroxylase 
deficiency" OR "PAH deficiency" OR hyperphenylalaninemia) AND 
(Caseinomacropeptide OR Glycomacropeptide OR GMP near/10 pku 
OR GMP near/10 phenylketonuria OR protein near/1 subst* OR 
“amino acid” near/1 formula OR “phenylalnine free”) 
British Library 
EthOS 
04/ 05/ 2018 33 Database of 
doctoral theses 
Doctoral dissertations from UK 
institutions (not comprehensive) 
Approach: Adavanced search limits searches to six terms. Separate 
searches were ran for “glycomacropeptide”, “GMP” 
“phenylketonuria” & “PKU” to increase sensitivity. 
Open Access 
Theses & 
Dissertations 
 
04/ 05/ 2018 1 Dissertation & 
thesis search 
engine 
Masters theses & doctoral 
dissertations. 
Approach: advanced search permits only 4 terms: “phenylketonuria 
OR PKU AND GMP OR glycomacropeptide” 
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Table 14: Database-type resources C. Clinical trial & results registries. 
 
Resource 
searched 
Date 
searched 
Number of 
raw results 
Resource type Types of reports included Approach used (no limits unless specified) 
International 
clinical trials 
registry 
platform 
(ICTRP) 
 
 
03/ 05/ 2018 127 trials Database of 
clinical trial 
registries 
World Health Organisation 
database completely covering 
most major regional/ national trial 
registries. There is & 1- 4 week lag 
when indexing registries but trials 
so recent will not have reported 
findings. 
Terms: Phenylketonuria OR PKU OR PAH deficiency OR 
hyperphenylalaninemia AND GMP OR Glycomacropeptide OR 
Caseinomacropeptide  
CenterWatch 
Clinical Trials 
Listing Service 
 
 
03/ 05/ 2018 7 Commercial 
database of 
clinical trial 
protocols 
Clinical trial protocols Only searches by condition permitted. Searched for “PKU” & 
“phenylketonuria”. 
Registries 
maintained by 
pharmaceutical 
companies 
03/ 05/ 2018 3 Trial protocol/ 
results 
registries 
Trial protocols and results which 
companies may only publish on 
their own registries.  
Approach: Separate searches for “PKU, phenylketonuria, GMP & 
glycomacopeptide” 
Companies included: Astrazeneca, Bayer, GSK, Eli Lilly, Bristol-Myers 
Squibb & Novartis. Most now register all trials on clinicaltrials.gov & 
its European equivalent and no longer maintain databases. 
clinicaltrial 
results.org 
03/ 05/ 2018 0 Website 
containing trial 
results  
Clinical trial results Approach: Separate searches for “PKU, phenylketonuria, GMP & 
glycomacopeptide” 
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Table 15: Snowball-type resources A. Reference list searches 
NB: results from these resources were screened as searches were conducted. 
Resource 
searched 
Date 
searched 
Unique, 
screened 
reports 
Description of resource Approach used (no limits unless specified) 
Reference lists 
of reports 
screened for 
inclusion 
16/ 05/ 2018 
 
0 
 
Searches of reference lists from studies that passed 
screening. 
Search: Searched manually & using ‘ctrl + F’ searches for “macro”, 
“glyco” & “GMP”. Unique results then screened for inclusion. 
Included studies: Abdel-Salam & Effat, (2010), Daly et al., (2017), Zaki 
et al., (2016), Ney et al., (2009),  van Calcar et al., (2009a), LaClair et 
al., (2009), Ney et al., (2016), Pinto et al., (2017), Ahring et al., (2018). 
 
Reference lists 
of reviews  
 
 
 
17/ 05/ 2018 
 
0 Searches of reference lists from reviews located via 
database-type resources and during the preceeding 
narrative review, for eligible studies 
Search: Searched manually & using ‘ctrl + F’ searches for “macro”, 
“glyco” & “GMP”. Unique results then screened for inclusion. 
Included reviews:  Blau et al. (2010) Harding & Blau (2010), Macleod 
& Ney (2010), Poustie & Wildgoose (2010), van Spronsen & Enns 
(2010), Blau, Hennerman, Langenbeck & Licther-Konecki (2011), 
Giovannini, Verduci, Salvatici, Paci & Riva (2012), van Calcar & Ney 
(2012), Ho & Christodoulou (2014), Ney et al., (2014), Strisciuglio & 
Concolino (2014), Al Hafid & Christodoulou (2015), Blau & Longo 
(2015), Yi & Singh (2015), Rocha & MacDonald 2016, Ney & Etzel 
(2017), Spécola & Chiesa (2017) 
Reference lists 
of clinical 
guidelines 
 
17/ 05/ 2018 
 
0 Searches of reference lists from clinical guidelines 
located via database-type resources and during the 
preceeding narrative review, for eligible studies 
Search: Searched manually & using ‘ctrl + F’ searches for “macro”, 
“glyco” & “GMP”. Unique results then screened for inclusion.  
UK guidelines:  Smith et al, (1993) 
German guidelines: Burgard et al., (1999), 
EU guidelines: van Spronsen et al., (2017), van Wegberg et al, (2017), 
USA Guidelines: NIH CDP (2001), Vockley et al., (2014)   
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Table 16: Snowball-type resources B. Citation searches 
Resource 
searched 
Date 
searched 
Unique, 
screened 
reports  
Description of resource Approach used (no limits unless specified) 
Citation 
searches of 
reports 
screened for 
inclusion 
17/ 05/ 2018 
 
0 Takes  reports, & doctoral dissertations (located via 
database-type resources) that passed screening and 
locates articles that have cited them which may be 
eligible for inclusion 
Search: Title of paper inserted into (a) Web Of Science (b) Google 
Scholar. Unique results (not already located) then screened for 
inclusion.  
Included Reports: See previous table 
Included Dissertations: See previous table 
Citation 
searches of 
reviews  
 
 
 
17/ 05/ 2018 
 
0 Takes reviews located via database-type resources  
and the preceeding narrative review and locates 
articles that have cited them which may be eligible 
for inclusion 
Search: Title of paper inserted into (a) Web Of Science (b) Google 
Scholar. Unique results (not already located) then screened for 
inclusion.  
Included reviews: See previous table 
Citation 
searches of 
clinical 
guidelines 
 
17/ 05/ 2018 
 
0 Takes guidelines located via database-type resources  
and the preceeding narrative review and locates 
articles that have cited them which may be eligible 
for inclusion  
Search: Title of paper inserted into (a) Web Of Science (b) Google 
Scholar. Unique results (not already located) then screened for 
inclusion.   
Included guidelines: See previous table   
 
Table 17: Snowball-type resources C. Handsearches of key journals 
Resource 
searched 
Date 
searched 
Unique, 
screened 
reports 
Rationale for handsearching Approach used (no limits unless specified) 
Molecular 
genetics & 
metabolism 
(journal) 
 
18/ 05/ 2018 2 Contained several relevant reports, particularly 
conference proceedings from the Annual Meeting of 
the Society for Inherited Metabolic Disorders (SIMD) 
and the  International Congress of Inborn Errors of 
Metabolism (SSIEM)  
(a) Web-based journal issues from 2007 (when GMP was first used in 
PKU) were searched for relevant articles using titles and abstracts, 
including in-press articles 
(b) Conference proceedings were searched manually and using ‘ctrl + 
f’ searches for “GMP”, “glyco” and “macro” 
(c) potentially relevant, unique papers were screened for inclusion 
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Resource 
searched 
Date 
searched 
Unique, 
screened 
reports 
Rationale for handsearching Approach used (no limits unless specified) 
Journal of 
inherited 
metabolic 
disease 
18/ 05/ 2018 1 Contained several relevant reports & abstracts from 
the Annual Symposium of the Society for the Study of 
Inborn Errors of Metabolism 
As above 
American 
journal of 
clinical nutrition 
18/ 05/ 2018 0 Contained several relevant reports As above 
 
Table 18: Snowball-type resources D. Manual searches of key websites 
 
Resource 
searched 
Date 
searched 
Unique, 
screened 
reports  
Resource type Types of reports included Approach used (no limits unless specified) 
Websites of 
manufacturers 
of PKU formulas 
& treatments 
14/ 05/ 2018 0 Company 
websites 
Published & unpublished reports of 
studies supporting products 
Approach: Site search facilities were used to search for “PKU, 
phenylketonuria, GMP & glycomacopeptide” & entire sites were 
handsearched using sitemaps. Potential reports were screened. 
Companies included: Biomarin, Cambrooke, Vitaflo UK, Vitaflo USA, 
Nutricia UK, Mead Johnson & Abbot Nutrition. 
Website of 
European PKU 
society (ESPKU) 
14/ 05/ 2018 0 Website of 
PKU Society 
Published papers & abstracts/ 
proceedings from international 
conferences. 
Approach: Site searched as above. Conference proceedings from 
2003 & 2012 were located on the NSPKU site (below) & reports 
screened for inclusion. Email correspondence indicates the content of 
other years conferences are only available to attendees.  
Website of 
English National 
PKU Society 
(NSPKU) 
14/ 05/ 2018 0 Website of 
PKU Society 
Published papers & abstracts/ 
proceedings from national 
conferences. 
Approach: Site searched as above.  
Conference proceedings from 1998- 2002, 2005- 2007 & 2016- 2018 
were located, handsearched & screened. Others were requested via 
email, but no response was received after 7 days. 
Website of US 
National PKU 
Alliance  
14/ 05/ 2018 0 Website of 
PKU 
association 
Conference presentations & 
funding awards which may identify 
studies. 
Approach: Site searched as above. Research projects funded by 
NSPKU & conference presentations from 2010 onwards were 
handsearched & screened for inclusion. 
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Resource 
searched 
Date 
searched 
Unique, 
screened 
reports  
Resource type Types of reports included Approach used (no limits unless specified) 
Website of 
canpku 
(Canadian PKU 
Association) 
14/ 05/ 2018 0 Website of 
PKU 
association 
Lists published studies & minutes 
from events. 
Approach: Site searched as above. Listed studies were screened for 
inclusion. 
Website of Irish 
PKU Association 
(pku.ire)  
14/ 05/ 2018 0 Website of 
PKU 
association 
None 
 
 
 
Approach: Site searched as above.  
Website of New 
South Wales 
PKU Association  
14/ 05/ 2018 0 Website of 
PKU 
association 
None Approach: Site searched as above. 
Website of 
British Dietetic 
Association 
14/ 05/ 2018 0 Website of 
dietetic 
association 
Abstracts from annual research 
symposiums, published in the 
journal of human nutrition & 
dietetics. 
Approach: Site searched as above. Most content requires 
membership. Symposium proceedings were available in issues of the 
journal of human nutrition & dietetics. Those dating back to 2008 
were handsearched, and relevant reports screened for inclusion. 
USA Academy 
of Nutrition & 
Dietetics site 
14/ 05/ 2018 0 Website of 
dietetic 
association 
Maintain a database of reviews & 
guidelines & the Journal of the 
Academy of Nutrition and Dietetics 
Approach: Site searched as above. The database is inaccessible to 
non-members & the journal is indexed by PubMed (searched above) 
Website of 
dietitians of 
Canada 
14/ 05/ 2018 0 Website of 
dietetic 
association 
Abstracts from annual 
conferences, published in the 
Canadian Journal of Dietetic 
Practice & Research. 
Approach: Site searched as above. Some content is inaccessible to 
non-members. Symposium proceedings are available in the Canadian 
Journal of Dietetic Practice & Research. Proceedings from 2008 were 
handsearched, and relevant reports screened for inclusion. 
Dietitians 
Association of 
Australia 
website 
14/ 05/ 2018 0  Website of 
dietetic 
association 
Conducts annual conferences & 
produces a journal. 
Approach: Site searched as above. Conference abstracts were not 
available and were requested via email but no response was received 
within the predetermined seven day window.  
Confederation 
of Dietetic 
Associations 
Website 
14/ 05/ 2018 1 Website of 
international 
dietetics 
confederation 
Conducts the international 
congress of dietetics (an 
international conference) every 
four years 
Approach: Site searched as above. Abstracts from the 2008, 2012 & 
2016 international congress conferences were handsearched. Others 
predate the first use of GMP in PKU (~2007) and the next is in 2020. 
Nutrition 
Society website 
(international) 
14/ 05/ 2018 0 
 
Website of 
nutrition 
society 
Conducts conferences & publishes 
six journals, one of which contains 
abstracts from these conferences. 
Approach: Site searched as above.  All six journals are indexed by 
pubmed (searched previously). Conference abstracts were searched 
as above. 
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6.1: Appendix 2: Example forms. 
Table 19: Blank screening Checklist 
Screening Criteria Yes, No, or 
Unsure 
Notes. 
Is the study in English?   
Are the participants human?   
Are the participants diagnosed with PKU?   
 
 
Does the intervention replace any amount of the participants usual 
amino acid formula with any amount and type of GMP?  
 
 
 
Are phenylalanine levels monitored?  
 
 
Does the study involve a control group?   
Does the study meet screening criteria?  
 
  
Instructions: Only reject reports clearly failing to meet one criteria. If unsure include the study but note the source of uncertainty. 
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Table 20: Blank inclusion criteria checklist 
 Screening Criteria and explanation. Yes, no, 
unsure 
Notes. 
 Are the participants diagnosed with  ‘conventional’ forms of PKU?  
--Studies containing subjects with BH4 defects (that require differential treatment)  and maternal PKU (which 
reduces tolerance and complicates management considerably) are excluded. 
 
 
 
 Where the patients treated during childhood (either at birth or late treated) and did they require dietary 
treatment to maintain control at the onset of the study? (whether currently receiving treatment or not)? 
--Studies involving untreated patients  are excluded as these are unrepresentative of the wider PKU population and 
may have severe neurocognitive disabilities impairing their ability to adhere to the protocol.   
--Patients with mild forms of PKU not requiring treatment to remain within recommended control ranges are also 
excluded. ‘Patients requiring treatment’ is specified for inclusion instead of severity thresholds as these are applied 
inconsistently (e.g. between countries) and the assessment of severity is problematic (its is determined before 
treatment at birth, often before blood phe peaks). Studies involving untreated or milder cases that provide 
separate data treated patients with ‘conventional/ classical PKU’ are permitted. 
 
 
 
 Are the patients free of other metabolic, liver and kidney conditions and other conditions that may affect protein 
metabolism?  
  
 Were patients receiving other treatments such as LNAA or Sapropterin? If patients are receiving sapropterin 
(synthetic BH4) co-treatment, was their phe tolerance stable before the study and was the sapropterin dose 
consistent throughout the study? 
--Exclude studies involving patients taking LNAA as their effects are not well characterised and may confound those 
from GMP in unpredictable ways. 
--Sapropterin (synthetic BH4) treatment is common in the USA and excluding patients receiving it would make 
recruitment difficult and reduce ecological validity but it has the potential to confound effects otherwise 
attributable to GMP if not used consistently throughout. 
  
 Is blood or plasma phe monitored at baseline and on at least one other occasion  during the study, for both 
conditions? 
  
 Is the full text of the study available in English?  Record foreign otherwise eligible. 
 Does the report meet inclusion criteria?   
Instructions: If unsure, describe the reason for this uncertainty in the notes column and continue to assess the report. The author will be 
contacted for clarification 
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Table 21: Example data extraction form 
Study Assessed  Ney et al., (2016). Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial 
Summary and Important Notes 
(complete after data extraction): 
Summary: Randomised crossover trial comparing control (using fasting measurements) in n=30 free living patients (mainly adults aged 
15-49y) during 3 weeks usual treatment (formula) to 3 weeks GMP treatment, separated by a 3 week washout on formula. There was a 
significant difference in control between conditions (using group means) due to a small but significant improvement on formula and a 
small, non-significant deterioration on GMP. However, whilst control was not totally equivalent between treatments: (a) the difference 
between conditions is of borderline clinical significance (b) the small loss of control noted on average for GMP (vs baseline) was not 
statistically or clinically significant (c) Responses varied individually: around 40% of patients maintained or improved control on GMP 
(d) Dietary phe intake increased significantly  (p = 0.0259) in the GMP condition (by 88 ± 6 mg Phe/d) despite the diets being designed 
to contain equal phe content, because subjects did not remove as much dietary phe (exchanges) as directed. Had exchanges been 
removed as directed, the difference between conditions and the extent of deterioration of control on GMP would have been even 
smaller and less concerning. However, it could be argued that this study provides evidence that (a) control can be modestly worse on 
GMP in some individuals (b) that the requirement to remove exchanges after GMP substitution is challenging and may promote 
control loss in some individuals. Careful monitoring and additional support/ education may be warranted. Ideally, the phe content 
would be reduced so fewer exchanges need to be removed and newer products are emerging with lower phe content. 
Links to supplemental tables, errata, 
claims of fraud etc. 
 
None 
 
Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Date of form completion  01-06-2018  
Author contact details 
(ideally an email address) 
To whom correspondence should be 
addressed. 
Professor Denise Ney 
ney@nutrisci.wisc.edu 
 
Publication type/ status  e.g. published, abstract, protocol Published Paper  
Unit of allocation e.g. individuals or cluster Individuals  
Study design (archetype)  
  
e.g. RCT, quasi RCT, crossover, NRS, 
other design (specify) 
Randomised crossover trial  
Detailed overview of study design Describe the overall design including: 
duration, whether parallel or serial, 
 which aspects are prospective 
Randomised crossover trial comparing 
control (fasting measurements) in n=30 
free living patients (adults aged 15-49y) 
during 3 weeks usual treatment (formula) 
to 3 weeks GMP treatment, separated by 
a 3 week washout on formula. 
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Number of participants  30  
Age of participants and baseline 
imbalances in parallel NRS. 
Range and average.  Studies are likely 
to only involve one group, or perform 
separate analyses on each. If they do 
not note imbalances as they may 
confound effects. 
15-49  
Do ages fit this reviews age 
brackets (<16 & 16 and over)> 
Note exceptions and consider in 
discussion/ appendices. 
No:  Age range is 15-49 but only 5 patients 
are under 17. 
Grouping this study with other adult studies in 
unlikely to negatively affect the review as: (a) only 5 
patients are under 17 (b) The tolerance and energy 
requirements of 15 year olds are similar to adults 
(unlike younger children) (c) The tolerance of all 
included patients were comparable and 100% 
replacement was performed in them all. 
The study was therefore grouped with other adult 
studies in this review. 
Population participants are drawn 
from and sampling design. 
E.g. university students, hospital 
patients, care homes? 
See quality assessment pt. 13 
PKU patients recruited from: 
(a) Biochemical Genetics Program, 
Waisman Center, University of 
Wisconsin-Madison   
(b) the Division of Genetics and Genomics, 
Boston Children’s Hospital,  
(c) Harvard Medical School  
(d)  National advertisement within the 
phenylketonuria community 
 
Setting & staffing arrangements e.g. inpatient, outpatient, university 
etc. 
 
Outpatient: patients were at home but 
returned to centres for blood phe 
measurements. 
 
Country  USA  
Number of centres (for study 
conduct) 
 2 centres 
Waisman centre (n=19) 
Boston Children’s Hospital (n=11) 
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Tolerances and baseline 
distribution between groups in 
parallel NRS. 
In mg phe (ideally) or g protein.  Note 
distribution imbalances and 
countermeasures in parallel NRS 
See quality assessment tool  pt 1 
Severity and baseline control data cover 
this 
 
 
 
 
Baseline Protein substitute 
prescriptions (g/ PE) and 
distribution between groups at 
baseline in  parallel NRS.  
Reflects tolerance as treatment is 
individualised by tolerance. Therefore 
unnecessary if tolerance is reported. 
Note distribution imbalances. 
See quality assessment tool  pt. 1 
 
Severity and baseline control data cover 
this 
 
 
 
 
Severity of condition and baseline 
distribution between groups in 
NRS (only to be used if previous 
two factors are unavailable). 
Does not reliably predict tolerance/ 
substitute requirements. Note 
distribution imbalances and measures. 
See quality assessment tool  pt 1 
Severities:  20 classical, 10 variant (based 
on genotype and response to synthetic 
BH4). 
 
 
See: (a)Characteristics of participants section 
 
Note point below 
Baseline control levels/ history of 
control and distribution between 
groups in  parallel NRS 
Potential confounder in NRS. 
See quality assessment tool  pt 1 
Baseline control levels: baseline plasma 
phe was significantly higher among 
patients with classical PKU (867 ± 73 
mmol/L) 
than those with variant PKU (461 ± 59 
mmol/L P < 0.001 
 
History of control: all subject early 
treated (shortly after birth). Optimal 
control was not required. 
 
Baseline control varied with severity and the initial 
ANOVA performed analysis suggested baseline 
control interacted with the main effect (I.E. the 
change between plasma phe at baseline and the end 
of each treatment period was different for patients 
with worse severities and higher baseline plasma 
phe). However, a pre-planned ANCOVA was 
performed that incorporated this potential source of 
confounding into analyses, so it is not problematic.  
Any important co-morbidities, and 
baseline distribution in  parallel 
NRS 
E.g. liver or kidney disease affecting 
protein metabolism. Note imbalances. 
See quality assessment tool  pt 1 
None 
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Type of formula administered 
(comparator)  
Format? (powder or modern?) 
Does it vary inter-individually? 
See quality assessment  pt 12. 
Format: Mixture of modern and 
traditional (some patients consumed 
more than one type): 
21 conventional powder in can 
4 powder in can or pre-portioned packets 
14 liquid ready to drink liquids 
2 pills 
Differences between subjects:  yes, usual 
treatment involving 15 different products 
Many subjects consumed modern versions of 
formula so this study is a  more fair and ecologically 
valid comparison than some others  
Type of GMP consumed 
(intervention) 
Format? (powder or modern?) 
Nutritionally complete?  
Used clinically or prelim form? 
Does it vary inter-individually? 
What is Phe content? 
See quality assessment  pt 12. 
Formats: self-selected modern foods ( 
pre-portioned drink mixes, pre-portioned 
pudding mixes, sports drinks)  
LNAA content: High vs formula (150% of 
USA RDI for Tyr, 130% for other limiting 
LNAA) 
Complete: yes  
Differences between subjects: yes, self-
selected 
Phe content: 1.8mg/ g PE (comprised of 
70% cGMP-20 from Arla Foods Ingredients 
and 30% supplemental AAs) 
Subjects selected their favourite GMP foods during a 
screening period. This is addressed below as a 
possible source of bias 
Notes: 
(a) LNAA:  His, Leu, Met, Trp, Tyr, Thr, Val, Ile, Phe. 
(b) GMP naturally high in: Thr, Ile. 
(b) Supplementation needed for: Arg, His, Leu, Trp, 
Tyr & Micronutrients. 
Proportion of formula replaced by 
GMP and dietary adjustments 
made? 
E.g. Replaced 100% and removed 
dietary exchanges to completely 
adjust.  
100% replacement. Dietary exchanges 
were supposed to be removed so diets 
contained equal phe between conditions 
 
Was dosing individually adjusted 
for tolerance/ severity or sub-
analyses performed? 
Flag for separate analysis for objective 
regarding individual variation in 
responses. Detail dosing strategy 
(tables/ figs) 
No: 100% replacement in all cases  
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Compliance levels with protein 
substitutes 
Total compliance and frequency of 
ingestion. Note differences between 
groups 
See quality assessment point 10 
Overall: Compliance was not significantly 
different between conditions (p = 0.576) 
and was considered “adequate” 
Prescribed Protein sub intake: 0.85 ± 
0.03g PE / kg BM / d 
Compliance with GMP via diaries:  0.74 ±  
0.04  g PE / kg BM / d 
Compliance with formula via diaries: 0.76 
±  0.05  g PE / kg BM / d 
Compliance with GMP using plasma Thr 
levels: 6 of 30 subjects displayed reduced 
plasma Thr between baseline and the end 
of GMP treatment, suggesting poor 
compliance in the 72hr before the blood 
draw. Sub-analysis excluding them did not 
alter study findings. 
Frequency: GMP was consumed 
significantly more frequently than AA 
(3.74 ± 0.24  Servings/d vs 2.43 ± 0.24  
Servings/d, p = 0.001), BUT only when 
comparing GMP and AA consumption 
during visits 3-4 (interaction with 
sequence noted via ANOVA, that was not 
specified a-priori in protocol or expected) 
 
(b) greater frequency of consumption with GMP 
was not noted overall: (only via an interaction with 
time in the ANOVA which was unexpected I.E. when 
comparing the 15 patients receiving GMP last to the 
15 receiving GMP last) This was clarified via email.  
Method of ensuring and assessing 
compliance with protein 
substitutes 
Method, timeframe and frequency of 
monitoring. 
See quality assessment point 10. 
(1) Total Intake and frequency of intake of 
GMP/ formula monitored through daily 
medical food logs (self-reports) 
(2) GMP intake objectively monitored 
using plasmas threonine. GMP is high in 
Thr and known to elevate plasma Thr. 
Reduced plasma Thr after stabilisation 
indicates poor compliance. 
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Compliance levels with dietary 
advice 
Particularly protein and energy intakes 
(total, frequency).  Note differences 
between groups. 
See quality assessment point 11 
Dietary phe intake increased significantly  
(p = 0.0259) in the GMP condition (by 88 ± 
6 mg Phe/d) despite the diets being 
designed contain equal phe content, 
because subjects did not remove dietary 
phe (exchanges) as directed in the GMP 
condition.  Intake of Phe from natural 
foods was not different between 
conditions and did not change significantly 
compared with baseline for either 
treatment. 
 
Method of assessing dietary 
compliance 
Method, timeframe and frequency of 
monitoring. 
See quality assessment point 11  
(a) 3 day food records completed before 
each study visit (baseline, end of AA, end 
of washout, end of GMP) 
Email correspondence suggests 
“Food diaries were largely estimated 
based on patient experience using 
household measures; a few patients did 
weigh their food with gram scale.” 
 
(b) Nutrient content estimated by skilled 
dietitian using Food Processor SQL and 
checked by second skilled assessor. Phe 
content of some foods incorporated using 
manufacturers information and Virginia 
Schuett’s Low Protein Food List for PKU 
(a) food diaries are error prone (they were mainly 
estimated though some were weighted) 
 
(b) Food diaries only covered the final 3 days of each 
3 week treatment period, these 3 days may not be 
typical  
Administration of co-interventions, 
noting imbalances 
e.g. BH4 or education. Note differential 
administration between groups. 
Patients receiving Sapropterin were 
eligible provided (a) their tolerance was 
stable (c) the dose of Sapropterin 
remained constant over the study.  
Note this and consider impact in quality assessment  
Duration of intervention periods, 
noting imbalances 
 3 weeks each, no imbalances   
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be 
requested from authors (note what is required) 
Time points measurements were 
taken at (duration, frequency, time 
of day) 
Also see Qual assessment point 9 (a) 4 fasting venous blood samples taken 
during study visits (1) baseline pre-AA (2) 
end of AA (3) baseline pre-GMP (4) end of 
gmp 
(b) dried blood spots taken at 8 points 
during each 3 week treatment period (on 
days 3, 6, 7, 10, 13, 14, 17, 21)  
 
Time points measurements were 
reported for 
Note discrepancies with above All reported  
How samples were collected 
 
DBS or blood? Plasma or serum? 
See Quall assessment point 9 
(a) Analysis of plasma AA concentration 
from venous blood samples using Hitachi 
L-8900 amino acid analyser (with post–
column ninhydrin derivatization ref  30 
therein). 
Interassay CV = 1.6% 
(b) Analysis of plasma phe from dried 
blood spots using  tandem MS and 
duplicate samples (nonderivatized flow-
injection method used for newborn 
screening). Interassy CV = 11.7%. 
 
 
How samples were analysed and 
validity/ reliability data for 
method 
E.g. MS-MS or Guthrie assays. 
See Quall assessment point 9 
Any differences between 
conditions in assessments? 
Potential to confound No.  
Were any sub-analyses performed, 
and were these selected a-priori? 
Report the analyses, findings and 
whether predetermined or post-hoc. 
In the ANOVA, an interaction was noted 
between the main effect (a comparison of 
the change in plasma phe from baseline 
between each condition) and 2 factors: 
(a) Baseline control level I.E. baseline 
blood phe – which varied with severity 
(being higher where severity was worse) 
(b) Dietary phe intake 
This was adjusted for by importing these 
factors as co-variates in a pre-planned 
ANCOVA.   
NB: some limited evidence of factors that predict 
inter-individual variation in responses to GMP: 
(a) baseline control level (baseline plasma phe) 
(b) severity (subgroup analyses suggested smaller, 
non-sig changes in control in milder variant forms – 
but lacked power) 
(c) dietary phe intake 
I.E. subjects with worse baseline control, severity 
and greater dietary phe intake saw greater changes 
in plasma phe so may be at greater risk of control 
loss. 
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Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be requested 
from authors (note what is required) 
Effect estimate, measure of 
variability and analysis used 
 
e.g. mean difference & standard 
deviation/ standard error/ 95% 
confidence intervals 
 
e.g. ANOVA, t-test 
Results (a) 
(a1) There was a significant difference 
between conditions:  (-147 ± 39  µmol/L ,  
p = 0.0008)  using mean ± SEM difference 
(a2) GMP-MFs showed a non-significant 
increase in plasma phe 62 ± 40 µmol/L, P = 
0.136)  (mean ± SEM) 
(a3) AA-MFs showed a modest, significant 
decrease in plasma Phe concentration 
(285 ± 40 µmol/L, P = 0.044)  (mean ± 
SEM)   
Analysis (a) using venous blood draws: 
Comparison of change in plasma phe from 
baseline to period-end (3 weeks) between 
conditions was investigated using 
ANCOVA to adjust for differences in 
baseline plasma phe and dietary phe 
intake (covariates). See next column for 
details. 
Results (b) The proportion of subjects 
showing an increase in plasma phe when 
comparing GMP to AA was not 
significantly different (p=0.267): 60% 
increased on GMP, 40% decreased on 
GMP. 
Analysis (b)  using venous blood draws: 
Proportion of subjects whose plasma phe 
rose between baseline and study end 
compared between conditions using 
Mcnemar’s Test. 
 
  
Analysis (a) : ANOVA conducted initially to compare 
changes in plasma phe from baseline to period-end 
between conditions (the main effect) and check for 
interactions with other variables. Interactions 
between the main effect and  (a) baseline plasma phe 
(b) ‘dietary phe intake’ were noted, so ANCOVA was 
performed, incorporating these factors as covariates. 
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Table 22: Example data request form 
Data request form:  Ney et al., (2016) 
Factor information is required for Example of type of information required Response from you RE information, with explanation 
where necessary 
 
Report that ‘frequency of consumption’ improved in 
GMP condition vs formula condition.  
Greater frequency of consumption was noted during 
the GMP condition, via an interaction with sequence in 
the ANOVA. It is unclear (to me) what is being 
compared here. Is this improved frequency of intake 
when comparing n=15 patients receiving GMP last to 
n=15 patients receiving AA last? 
--Can you please (a) clarify this (b) confirm that no 
interaction with sequence was expected (b) confirm 
that this analysis was not specified a-priori? 
Yes, your interpretation is correct; it made stats for 
subjects during their 2nd or last of the two treatments.  
We did not expect that the order of treatments would 
affect the results, but tested for a sequence effect in all 
analyses.  
Analysis for frequency of MF intake was included in the 
approved protocol before subject recruitment began; it 
was a secondary outcome.  
Factor  Explanation of factor and information 
required 
Description of factor as stated in study 
and location (e.g. methods)  
Notes or missing information that must be requested 
from authors (note what is required) 
Statistical significance reported 
and significance level used 
e.g. p = 0.02 at significance level of 
0.05 
See above (a = 0.05)  
Sample size for effect, if different See quality assessment pt. 14 Same  
Was power calculation performed? See quality assessment pt. 14 Yes: “The trial was powered at 
80% (b = 0.20) based on a previously 
reported SD of 150 mmol/L for plasma 
Phe (20, 32) to detect a change in plasma 
Phe of 120 mmol/L at a = 0.05 (2-sided 
test). This provided a sample size of 25 
subjects. 30 subjects were recruited with 
an estimated dropout rate of 15-20%. 
 
Did study have adequate power 
and precision? 
See quality assessment pt. 14 Power: yes, see above 
Precision: yes 
 
Overall appropriateness of analysis 
and impact on findings/ weighting 
See quality assessment pt. 14 Analyses appear suitable  
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Factor information is required for Example of type of information required Response from you RE information, with explanation 
where necessary 
Method of assessing dietary compliance Were food diaries weighed or estimated, and what 
method was used for weighing/estimates? 
Food diaries were largely estimated based on patient 
experience using household measures; a few patients 
did weigh their food with gram scale.  
Random sequence generation Randomisation of treatment order was employed.. 
“Equal randomization of the diet treatment order was 
achieved by using a computer-generated scheme.” 
However, 10 subjects that found GMP unacceptable 
during a screening period were not enrolled. 
 
I assume randomisation occur after this screening 
period? 
Yes, if GMP unacceptable then not enrolled.  
 
 
 
 
Yes, randomization occurred after screening and 
consenting – at the time of enrolment.   
Concealment of  
allocation  
Were upcoming allocation concealed?  
What method was used? 
No subjects and research staff knew the allocation so 
they could counsel subjects.  
NB:  misinterpreted as ‘unblinding’. Randomisation 
confirmed as adequate via subsequent email. 
Blinding of participants and personnel  Blinding of participants? (yes/ no) 
Blinding of personnel? (yes/ no) 
Method? 
 
No blinding, impossible as products taste and look very 
different.  
Blinding of outcome assessment Blinding? 
Method? 
“ 
Incomplete outcome data I note two subjects dropped out because 
they were unable to complete requirements of the 
protocol because of time constraints 
How much data was obtained for them, and how was 
their dropping out handled? 
Both dropped out within 1st week of first treatment.  
Very little data was obtained other than baseline and 
no data was included in analysis from these 2 subjects.     
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Table 22: Example quality assessment form: 
 
Quality assessment form: Ney et al., (2016) 
Design feature (and 
number for guidance 
notes)  
Risk of bias, confounding, 
imprecision or poor 
external validity. 
(unclear, low, high or n/a) 
Explanation of decision, with explicit reference to 
methods used and measures taken to minimise 
impact. 
Where risk is high or unclear, how important is this 
source of bias/ confounding and what is the likely 
direction and magnitude of its impact. 
 
Random sequence 
generation (1) 
 
 
Low risk of bias  
(from order of treatments 
or trends over time) 
 
The order of treatments was generated  using 
computer-based randomisation considered adequate 
by Cochrane guidance and ANOVA found no evidence 
of sequence effects so randomisation was adequate. 
 
 
NB. Subjects sampled GMP and those finding it 
unacceptable were excluded from the study but this 
occurred before randomisation at the sampling stage. It is 
therefore considered a threat to external validity in point 
10. 
Concealment of  
allocation (2) 
 
 
Low risk of bias  
(from order of treatments 
or trends over time)  
 
The randomisation scheme prevented knowledge of 
upcoming assignments (clarified via email). 
  
Blinding of 
participants and 
personnel (3) 
 
High risk of bias  
(Performance bias) 
Blinding not mentioned in manuscript but email 
correspondence confirms patients and personnel 
were aware of allocations. 
 
Blinding of outcome 
assessment (4) 
 
High risk of bias 
(Performance bias) 
Blinding not mentioned in manuscript but email 
correspondence confirms outcome assessors were 
aware of allocations.  
 
 
Incomplete outcome 
data (5) 
 
 
Low risk of bias 
(Attrition bias) 
n=2 patients dropped out in first week, stating they 
were unable to complete the requirements of the 
protocol because of time constraints. 
Email correspondence confirms that they provided 
little data besides baseline data and were totally 
excluded from analyses.  
When. subjects withdraw during the first condition of  
within-subjects design and provide no data for the second 
it is common to totally exclude them from analyses, as 
done here (Higgins et al., 2017). This may bias results if 
reasons relates to prognostic factors or outcomes (Mills et 
al., 2009). In this case reasons relate to general demands 
of the study (e.g. completing food diaries and blood 
draws) rather than aspects specific to one treatment arm. 
Attrition was also low. 
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Design feature (and 
number for guidance 
notes)  
Risk of bias, confounding, 
imprecision or poor 
external validity. 
(unclear, low, high or n/a) 
Explanation of decision, with explicit reference to 
methods used and measures taken to minimise 
impact. 
Where risk is high or unclear, how important is this 
source of bias/ confounding and what is the likely 
direction and magnitude of its impact. 
 
Selective outcome 
reporting (6) 
 
 
Low risk of bias 
(selective reporting) 
No evidence of selective reporting was noted after 
comparing the methods section to the results section 
and comparing the study to the registered protocol 
Some non-relevant outcomes described in the 
protocol are published in a separate study. 
 NB this column was largely redundant as the question 
was addressed in table 2 
Carryover in within-
subjects designs .e.g. 
crossovers (7) 
Low risk of bias 
(carryover) 
Washout duration and protocol: Extensive washout 
period: 3 weeks on usual formula. 
Statistical tests for carryover: ANOVA found no 
evidence of carryover or sequence effects. 
Reason to expect carryover: no logical reason to 
expect carryover as PKU is a stable, chronic condition 
that cannot spontaneously improve or deteriorate 
and GMP and formula have short-lived effects. 
 
Influence of funding 
source (8) 
 
 
 Low risk of bias 
 
Study was funded via government grant but principal 
author has commercial links to GMP products at 
market and a manufacturer provided the GMP used. 
However,  Cochrane and AHRQ guidance requires 
compelling evidence that funding sources or 
industrial links have increased the risk of specific 
sources of bias. There is no such evidence herein. 
 
Validity and reliability 
of outcome 
assessment (9) 
Low risk 
(of measurement error) 
 (a) Measurements for main effect  (comparing 
average change in plasma phe from baseline to study, 
between conditions) used venous blood samples 
analysed via an Hitachi L-8900 amino acid analyser 
with post–column ninhydrin derivatization.   
(b) Measurements for secondary analyses (comparing 
control at intermediate timepoints over each 3 week 
period) was via duplicate dried blood spots analysed 
via tandem MS (nonderivatized flow-injection 
method used for newborn screening).  
(c) all samples were collected from 9.00 – 9.30 after 
an overnight fast. 
(a) Interassay CV for  Hitachi L-8900 = 1.6% and systematic 
errors with modern methods such as this are comparable 
and inconsequential  van Wegberg et al., 2017).  
(b) Phe content of bloodspots is generally 8-28% lower 
than plasma/ blood but this varies individually (van 
Wegberg et al., 2017) and the interassay CV using DBS 
and tandem MS is wide (~11.7%). However, the authors 
only compare blood spot data to itself and use it as 
secondary measure for triangulation. 
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Design feature (and 
number for guidance 
notes)  
Risk of bias, confounding, 
imprecision or poor 
external validity. 
(unclear, low, high or n/a) 
Explanation of decision, with explicit reference to 
methods used and measures taken to minimise 
impact. 
Where risk is high or unclear, how important is this 
source of bias/ confounding and what is the likely 
direction and magnitude of its impact. 
 
External validity (10)  High risk 
(of poor external validity) 
Completeness of GMP: (a) A complete, commercial 
form of GMP was used, (Glytactin) recreating clinical 
practice. 
Fairness of comparison: (b) Modern and 
conventional versions of GMP were compared to 
modern and conventional versions of formula, a fair 
comparison that recreates clinical practice. 
Setting: (c) Subjects were outpatients, recreating 
clinical practice. 
Sample selection and other threats to external 
validity: Subjects sampled GMP before randomisation 
and those finding it unacceptable were excluded. 
Participants then self-selected GMP foods. This is 
(arguably) unlikely to occur in practice. 
Importance: high 
 
Direction and magnitude of influence: Selectively 
recruiting patients that favour GMP would be expected to 
overstate GMPs benefit when considering the entire PKU 
population, some of whom may not prefer it.  
Appropriateness of 
sample size and 
statistical analyses 
(11) 
Low risk 
(of poor power/ precision) 
Power calculation: (a) Power calculation was 
performed to ensure study was adequately powered:  
“The trial was powered at 80% (b = 0.20) based on a 
previously reported SD of 150 mmol/L for plasma Phe 
to detect a change in plasma phe of 120 mmol/L at a 
= 0.05. This provided a sample size of 25 subjects. 30 
subjects were recruited with an estimated dropout 
rate of 15-20%.” 
Sample size: see above 
Appropriate analyses? Appropriate analyses were 
used (ANOVA). 
 
Other study/ design-
specific threats to 
quality, bias or validity 
(12) 
Low risk 
 
None  
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6.2: Appendix 3: PRISMA-P Compliant protocol 
Headings correspond to PRISMA-P requirements. 
Methods that were changed after producing the protocol are crossed out. Explanations are 
provided in  bold italics. 
Item 1: Administrative information. 
1a: Identification 
The effect of replacing conventional amino-acid formulas with glycomacropeptide-based 
alternatives on phenylalanine control in adults and children with phenylketonuria: Protocol 
for a systematic review. 
1b: Update 
The review is original. 
Item 2: Registration 
A protocol adhering to PRISMA-P guidelines was produced before starting the review. This 
was undertaken to ensure transparency and prevent bias by ensuring methods and analyses 
were determined in advance, to plan the review process, to educate the first-time reviewer 
regarding good practice and to ensure items required for PRISMA reporting standards were 
addressed. The protocol was included in appendices and modifications/ deviations from it 
were noted. However, it was considered beyond the scope of the assignment to publish the 
protocol prospectively. 
Item 3: Authors 
3a: Contact information & 3b: Contributions 
Contact 1: Mr Roderick Thomson, University of Chester, 1622331@chester.ac.uk, 8 Apsley 
Avenue Wallasey Merseyside 
Role: MSc student, protocol author and sole reviewer. 
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Contact 2: Sohail Mushtaq, University of Chester 
Role: Masters Dissertation supervisor. 
Item 4: Amendments 
Amendments to the protocol occurring after initiation of the review are inevitable as the 
nature of the evidence reviewed cannot always be anticipated. To ensure transparency, 
methods that were altered are included but crossed out. Explanations are provided in  bold 
italics. 
Item 5: Support 
No financial support or sponsorship was received. Academic advice was received from the 
dissertation supervisor and the review was conducted by the sole author. 
Item 6: Rationale 
The in-born error of metabolism Phenylketonuria was associated with severe 
neurocognitive disabilities that usually required lifelong residential care before dietary 
treatment was widely adopted. Dietary treatment restricts dietary phenylalanine intake to 
‘control’ plasma phenylalanine levels, preventing phe accumulating to toxic levels. As the 
developing CNS is most vulnerable to phe, treatment is initiated at birth and strict control 
(via strict dietary restriction) is essential during childhood to avoid the most severe defects.  
Some relaxation of control is permitted in adulthood but lifelong treatment is universally 
recommended as subtler neurocognitive defects occur if treatment ceases. Since the 
widespread adoption of dietary treatment, the severe disabilities that were previously 
associated with PKU have become rare. However, intelligence levels and several aspects of 
health remain suboptimal even among early-treated PKU patients, partly due to limitations 
of conventional dietary treatment. Adherence proves difficult as phe is ubiquitous in 
proteins so, in practice, most protein-containing foods must be restricted. Particularly 
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problematic are the synthetic amino-acid based protein substitutes (formulas) prescribed to 
meet outstanding protein requirements, which lack acceptability and satiety.  
GMP is whole protein found in whey that is naturally free of phenylalanine. It is used to 
manufacture therapeutic foods that form a novel alternative to formulas and may improve 
dietary treatment and patients health in several ways. Evidence linking GMP to 
improvements in long-term health outcomes is lacking, owing to its recent development, 
the low prevalence of PKU and ethical concerns which make conducting trials difficult. 
Nevertheless, preliminary evidence suggests GMP is widely considered more acceptable 
than formula and that it may (for example) improve bone health,  satiety and 
gastrointestinal comfort. However, GMP contains some phenylalanine as its purification 
from other phe-containing constituents of whey is imperfect. This residual phe raises 
concerns around the impact of GMP foods on control and their safety, particularly in 
children who are more sensitive to phe. Despite GMP being licenced in several countries for 
use in over 4s, these concerns remain unresolved. The scoping review conducted whilst 
planning this review attempted to resolve these concerns using narrative methods. Its 
findings suggested both adults and children can maintain control after replacing formula 
with GMP but that individualised titrations (adjusting the amount of formula replaced by 
GMP rather than simply replacing all formula) may be necessary in some children. 
Equivalent control would be a positive finding given GMPs other potential advantages. 
However, the review located only seven primary studies, most lacking randomisation and 
employing low quality, bias-prone, and heterogeneous designs. Other GMP reviews located 
used narrative methods and were concentrated within a single group with commercial links 
to GMP products, raising objectivity concerns. GMPs effect upon control in both adults and 
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children thus requires clarification using systematic methods that attempt to synthesize the 
entire evidence base and consider the impact of design quality, risk of bias and 
heterogeneity upon results.  
Item 7: Objectives 
This systematic review aims to clarify the effect of totally or partially replacing amino-acid 
based protein substitutes with GMP-based alternatives upon blood phenylalanine levels (I.E. 
‘control’) in adults and children with phenylketonuria. As phe tolerance, protein 
requirements, formula requirements and several other aspects of care differ markedly 
between adults and children, the review separately analyses and presents data from studies 
involving adults (≥16) and children (3- 16). The following objectives are considered 
separately in both age groups. 
Primary Objective: Through a systematic review using predetermined, evidence-based 
methods, determine the effect of replacing formula with GMP-based foods upon plasma 
phe control by narratively synthesizing studies and considering the impact of design quality, 
bias and heterogeneity upon their results.  
Secondary Objective 1: Determine the influence of GMP upon compliance with therapeutic 
diets, and whether GMP-induced compliance changes lead to improvements, maintenance 
or deterioration of control. This will be accomplished by comparing compliance levels and 
control data between studies whilst considering the validity and reliability of methods used 
to monitor compliance.   
Secondary Objective 2: Most studies compare newly developed ready-to-eat, food-like GMP 
products (e.g. snack bars) to patients usual formula. In studies where this formula is 
predominantly in traditional powdered formats, the comparison may be considered 
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misleading as more modern versions of formula are available. Clarify the impact of 
this upon findings using narrative sub-analyses.  
Secondary Objective 2: Data permitting, clarify the effect upon plasma phe of only partially 
replacing formula with GMP. Among  children, 100% replacement may be impossible due to 
low tolerances and high formula requirements. In adults the strategy may also prove useful 
(for example) in patients struggling to comply.  
Secondary Objective 3: Data permitting, describe the extent of inter-individual 
variation in plasma phe responses or the amount of formula replaceable with GMP, and 
explore this variation as this may inform clinical practice by helping to identify patients likely 
to respond well to GMP.  
The above objectives were addressed within the review but not as standalone objectives, 
as it was felt that so many objectives fragmented analyses particularly when the factors 
considered are all inter-related.  
Secondary Objective 4 (children only): Consider whether GMP treatment remains 
worthwhile where only small quantities are permissible  
Secondary Objective: 5 (children only) Consider whether improved purification 
techniques could reduce GMPs phe content, as this limits its utility most. 
These objectives were removed as the data collected does not address them, and 
answering them essentially requires ‘another review’ something the handbook warns 
against 
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Item 8: Eligibility criteria 
Rationale: Inclusion criteria were developed using PICOS to favour inclusivity and adherence 
of studies to them was ensured using screening and inclusion criteria forms. Rather than 
exclude studies during screening and eligibility assessments, the criteria selected considered 
most controlled human studies comparing GMP to formula acceptable. This involved 
incorporating more bias-prone and low-quality designs, though the quality/ risk of 
assessment process and subsequent narrative analyses considered the impact of design 
quality and bias upon findings. The approach also increased heterogeneity between studies, 
making it more difficulty to attribute changes in control to study-level or individual-level 
factors, as sources of heterogenity confound sub-analyses during narrative analysis.  The 
approach was considered necessary despite these drawbacks given the few, low-quality, 
heterogeneous studies located in the scoping review.  
Criteria: See screening and inclusion criteria forms for the criteria used. 
Item 9: information sources 
Guidance consulted: Information sources were selected and the search strategy formulated 
using Guidance from the Cochrane collaboration’s handbook, the Centre for Reviews and 
Dissemination (CRD, 2009), the Agency for Healthcare Research and Quality (Relevo & 
Balshem, 2011) and the university information specialist. 
The review aims to minimise publication bias whilst increasing sensitivity by searching a 
wide variety of sources of published and unpublished (or grey) literature.  
Language restrictions: Only English language papers are include despite the possibility this 
may introduce language bias, as translation facilities are unavailable. 
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Date restrictions: no date restrictions are specified as records can be mis-indexed. 
The resources searched where divided into database-type resources (searched first) and 
snowball-type resources that were identified from the results of the data-base type 
resources, after removal of duplicates and screening. 
Database-type resources 
See tables 12 -14 (appendix 1) 
Snowball-type resources 
As several of these resources were identified from the screened studies obtained from 
database-type resources, they could not be specified in advance.  
1. Reference list searches: Included screened studies from database-type resource 
searches and reviews and guidelines located during the scoping review and from 
database-type resources 
2. Citation search tools: titles of screened studies from database-type resource 
searches and reviews and guidelines located during the scoping review and from 
database-type resources were searched for 
a.  Web of Science 
b. Google Scholar 
c. Scopus could not be used as host institution does not subscribe to service 
3. Handsearching key journals:  (all identified through database-type resources) 
a. Molecular genetics metabolism  
b. Journal of inherited metabolic disease 
c. American journal of clinical nutrition 
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4. Manual searches key websites (some were identified iteratively from other 
organisations sites) 
a. Sites of companies producing GMP medical products sites (Biomarin, 
Cambrooke, Vitaflo UK, Vitaflo USA, Nutricia UK, Mead Johnson & Abbot 
Nutrition) 
b. PKU/ IEM society websites (e.g. ESPKU, NSPKU, NPKUA, Canadian PKU 
Association, PKU.IRE, New South Wales PKU Association, IEM Societies 
c. Dietetic. Nutrition Society Web sites (BDA, USA Academy of Nutrition & 
Dietetics, dietitians of Canada, Dietitians Association of Australia, 
Confederation of Dietetic Associations, Nutrition Society) 
5. Ensuring all relevant studies have been identified by sending a list to experts 
a. Sent list to Professor Denise Ney  
Item 10: Example Search Strategy 
Rationale: The search strategy favours sensitivity over precision for aforementioned 
reasons. As varied non-randomised designs are included, search terms do not restrict results 
by design and relate only to the ‘Condition’ and ‘Intervention’ aspects of PICOS (Reeves et 
al., 2011). As per evidence-based guidelines (CRD, 2009 page 245) few concepts (condition 
and intervention) are combined using the Boolean operator ‘AND’ but many synonyms for 
each concept are grouped using ‘OR’ and truncation via wildcards.  To increase sensitivity 
terms use natural language alongside database-specific subject headings (e.g. MeSH terms) 
which can be assigned inconsistently or slowly by indexers (Relevo & Balshem, 2011). 
Subject headings were ‘exploded’ where possible to include sub-topics in results.  
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A strategy specific to Pubmed was first devised by adapting the Cochrane Collaboration’s in-
born error of metabolism search strategy. This was pilot tested by ensuring it retrieved 
relevant articles known to be indexed therein. The syntax and terms of the strategy were 
then adapted for other databases and resources.  The strategy and adaptation process were 
then checked against a peer-reviewed checklist (McGowan et al., 2015) and finalised 
through consultation with an information specialist.  
Pubmed Search strategy: Phenylketonurias OR Phenylketonuria OR PKU OR "Phenylalanine 
hydroxylase deficiency" OR "PAH deficiency" OR hyperphenylalaninemia AND GMP OR 
Caseinomacropeptide OR Caseinomacropeptides OR Glycomacropeptide OR 
Glycomacropeptides OR "Protein substitute" OR "Protein substitutes" OR "amino acid 
formula" OR “phenylalnine free” 
Adaptation Process for other resources 
1. Check the database/ resource basic rules, controlled vocabulary & explosion rules 
2. Check use of wildcards for truncation  
3. Check rules for plurals, quotations and adjacency 
4. Check ‘tags’ to increase precision if needed. E.g. [TIAB] & [TW] – some databases 
require them (WoS) 
5. Adapt the strategy using 1-4, checking for reports of syntax errors etc. 
6. Pilot the adapted strategy by searching for records known to be indexed therein 
Item 11a: data management 
Reference management software (Zotero) was used to maintain a database of studies 
throughout the entire review. The last date and details of searches were recorded in a table 
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that will be published. Database-type resources were searched first and results pooled in 
the software. Duplicate reports were removed automatically then manually and remaining 
reports were then screened using the screening form.  
These screened reports were used to direct searches of snowball-type resources. Their 
reference lists were searched for unique reports and their titles were inserted into citation 
search tools, along with relevant reviews and guidelines located via database resources and 
during the preceeding review. Handsearches of journals were restricted to those that 
generated the most relevant reports during database searches. Potentially relevant reports 
from snowball-type resources were screened as they were encountered. 
A final pool of screened reports was formed to detect different reports of the same study by 
comparing several study characteristics including authors, sample sizes and outcomes (CRD, 
2009 page 25). Reports describing the same study were merged but all reports were 
retained to provide additional detail and check for publication bias. Where full text was 
unavailable (e.g. for proceedings or protocols) or clarification was required, authors were 
contacted via email which is quicker and may increase response rates (Relevo & Balshem, 
2011). A window of seven days was allowed for responses. 
 Zotero was replaced by EndNote during searches of database-type resources, to improve 
compatibility with the bulk data export formats used by different databases. 
Item 11b: Selection process 
Abstracts and titles of articles were initially screened for inclusion using a screening form 
favouring inclusivity and speed of use. The full text of potentially relevant articles was then 
checked against a more detailed inclusion criteria form, though given the open nature of the 
review this also heavily favoured inclusivity. Both forms were developed a-priori using PICOS 
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to minimise bias, piloted using eligible, ineligible and borderline studies and are included in 
appendices. Whilst repetition of screening and study selection by a second, blinded 
reviewer with another speciality can minimise errors neither was possible.  
A PRISMA flowchart is included in the review. 
Item11c: Data collection process 
A standard data extraction form was developed using evidence-based guidance a-priori to 
minimise bias then piloted using studies meeting the inclusion critera. It is included in 
appendicies. The form was developed and used alongside the quality assessment tool to 
ensure data required for quality assessment was also collected. A single reviewer extracted 
data though the process was double-checked to reduce errors. Where important details 
were missing, clarification was requested from authors via a standard email. If no response 
was received within seven days the information in question was marked ‘unclear’. Studies 
providing insufficient information were excluded if this was subjectively deemed necessary, 
and this decision explained and its impact on findings considered. 
Authors were allowed 18 days to respond to increase the likelihood of responses, not 
seven 
Item 12: Data items collected. 
See the data extraction form and quality assessment tool in appendices, where all data 
items are collected for are incorporated. Forms were developed in advance to avoid 
selective reporting and data items were selected using PICOS. As NRS are included, potential 
sources of confounding were identified. Where these related to participant-level 
characteristics in parallel studies (e.g. tolerance or history of control) their baseline 
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distribution between groups was investigated as imbalances may introduce selection bias. 
Sources of confounding relating to behaviours (e.g. dietary confounding or non-compliance) 
were assessed in separate domains of the quality assessment tool. 
Item 13: Outcomes data is collected for 
Primary outcomes: the mean difference in plasma phe (in micro moles/L) when comparing 
GMP treatment to control groups (usual treatment with AA formula), noting the amount of 
formula replaced by GMP (where applicable). The direction, magnitude, power, precision 
and clinical significance of effects will be noted. 
Analysis of harm: is encompassed in the primary objective as decreases in control of 
sufficient magnitude are dangerous, particularly in childhood. 
Secondary outcomes: Compliance levels with protein substitutes (quantity, frequency) and 
dietary requirements (protein and energy intakes)    
Justification of using a surrogate: As neurocognitive defects such as impairments in 
intelligence and executive functions form the major source of morbidity in PKU, 
neurocognitive outcomes are most important. However, detectable changes in such 
outcomes accumulate over timespans that are impractically long to investigate. Historical 
prospective studies investigating the effect of dietary treatment upon such outcomes were 
plagued by poor compliance and patients ‘crossing over’ to conditions other than those they 
were initially randomised to (Poustie & Wildgoose, 2010). Given GMPs recent development 
no studies administering GMP located in the scoping review monitored such outcomes. 
Further, neurocognitive outcomes are assessed using a variety of indices that are difficult to 
compare (van Spronsen, Huijbregts, Bosch & Leuzzi, 2011). Whilst the pathophysiology of 
PKU is not totally understood, plasma phe concentration is the only physiological variable 
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implicated in every theoretical pathophysiological mechanism that is routinely measurable 
in research/ clinical settings and large meta-analyses show longer-term plasma phe levels 
robustly predicting neurocognitive outcomes (Waisbren et al., 2007; Fonnesbeck et al., 
2012; Albrecht et al., 2009). Plasma phe concentration is thus most well-established and 
widely used marker in the study and treatment of PKU. Elevations are used to diagnose PKU 
in newborns and treatment guidelines advise the maintenance of levels associated with 
neurocognitive outcomes most resembling population norms through dietary phe 
restriction and blood monitoring (van Wegberg et al., 2017). Any validated assessment 
method (for blood/plasma phe) was considered acceptable but the impact of the validity 
and reliability of the method selected was evaluated during quality assessment and the 
narrative analysis. 
Item 14: Assessing design quality and risk of bias 
The risk of bias of included studies was assessed via  quality assessment tool that was 
initially based on the Cochrane risk of bias tool. This assesses studies across six ‘domains’, 
each of which addresses a design feature which theory or empirical evidence suggests can 
introduce bias.  (1) Random sequence generation (2) Concealment of allocation (3) Blinding 
of patients & personnel (4) Blinding of outcome assessments (5) Incomplete outcome data 
(6) Selective outcome reporting.  For each domain, studies were assigned ‘high’, ‘low’ or 
‘unclear’ risk of bias, using Cochrane guidance. Ratings were assigned only after requesting 
missing data from authors, as above. The tool was favoured for several reasons. It 
distinguishes conduct (which may introduce bias) from reporting (which may reflect details 
being omitted due to word counts). It also forces the reviewer to explain decisions and the 
weighting attached to each domain for each study in words, with explicit reference to the 
study manuscript. This ensures applicability, transparency and accountability. 
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Within-subjects designs (e.g. crossovers) are common in PKU to control for individual 
differences in baseline control and tolerance and to reduce sample size requirements, given 
the condition’s low prevalence. The tool was adapted to evaluate crossover studies using 
Cochrane guidance (Higgins et al., 2011). An additional domain evaluating the risk of 
‘carryover’, a form of bias unique to crossovers, was added and the domain regarding 
attrition was modified.  
Further adaptations were necessary to evaluate NRS. Cochrane guidance directed these 
(Reeves et al., 2011). As randomisation is not performed, parallel NRS are particularly 
susceptible to selection bias I.E. systematic differences in the distribution of potentially 
confounding factors between groups at baseline. Therefore, potential confounders (e.g. 
tolerance, age) were identified a-priori, and the data-extraction and quality assessment tool 
considered their distribution between groups at baseline and any attempts to compensate 
or balance groups. 
Studies with inadequate randomisation were considered innately at risk of selection bias 
as statistical adjustments and  efforts to balance prognostic factors between groups do 
not reliably prevent selection bias (Deeks et al., 2003), so the above was not performed. 
In order to assess every aspect of study design quality at once the tool also evaluates design 
features that influence the confidence that can placed in a study’s findings and their 
applicability, but that are not included in the Cochrane risk of bias tool as they do not relate 
to bias perse. These include factors affecting the power & precision of studies (which a 
meta-analysis would incorporate but a narrative analysis may overlook), factors affecting 
external validity and the extent to which compliance with treatment and dietary 
confounding affect findings. The Downs & Black checklist assisted when identifying these 
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factors (Downs & Black, 1998). A ‘catchall’ domain relating to design-specific sources of bias 
(e.g. recall bias in retrospective designs) was also included. Guidance notes were produced 
for the quality assessment tool. Where insufficient information to form a judgement was 
available for certain domains, clarification was requested from authors via email. If no 
response was received within 18 days, the domain was marked as unclear. 
Item 15: Data synthesis 
Given the bias-prone, heterogeneous studies located in the scoping review and that the 
direction of effect varied between studies, quantitatively pooling results would be 
misleading. It may obscure ‘real’ differences between results (due to heterogeneity) and 
may add unwarranted credibility to findings, given the bias-prone designs included. Instead, 
narrative analysis was performed using a structured approach based upon guidance from 
the CRD (2008, page 48) and particularly Popay et al., (2006). It was not possible to select 
the precise analysis methods to be used in advance. However, the variables analyses are to 
focus on were planned and listed below a-priori. Any analyses added afterwards as they 
were not anticipated or emerged from the data are marked separately and explained. This 
approach aims to avoid unnecessary post-hoc analyses or ‘data-dredging’ which in a 
quantities study would increase the chance of cumulative errors. In this narrative analysis 
they increase the likelihood of factors without plausible ways of influencing control being 
spuriously identified as important. 
Analyses planned a-priori 
 (a) Separate analyses by age: As tolerance, the amount of formula replaceable by GMP and 
several other aspects of treatment differ markedly between adults and children, studies will 
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be separated to form separate reviews for adults for children.  All subsequent analyses are 
performed in both groups separately. 
NB: Note on Influence of heterogeneity on differences in effects between studies: Given 
the varied designs included, many sources of heterogeneity are likely to remain between 
studies despite dividing them by age. Examples include 
(a) Samples with different severities of PKU, phe tolerances (both related – and 
inextricably linked to intensity of treatment as restriction and formula requirements 
are greater in severe cases) 
(b) Differences in baseline control between samples  
(c) Differences in patients and history of control/ compliance with treatment  
(d) Use of different types of GMP (e.g. different LNAA content) 
(e) Use of different types of formula  
These sources of heterogeneity are likely to complicate/ confound sub-analyses attempting 
to attribute differences in effect estimates between studies (or differences in control 
between subjects, within studies) to factors suspected to explain them. To illustrate; studies 
divided into subgroups differing by one variable of interest (e.g. randomisation) to 
investigate its impact upon control are also likely to differ in the distribution of other 
variables that influence control (e.g. severity) confounding the comparison.  
(b): Assessing the impact of bias and design quality upon the direction and magnitude of 
findings (primary objective 1): These comparisons should ascertain the impact of design 
quality/ bias upon findings which heavily influences how much confidence can be placed in 
the findings reported. As most forms of bias/ design limitations tend to overstate an 
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interventions benefits, more supportive (but less credible) findings would generally be 
expected from lower quality, bias-prone studies and less supportive (but more credible) 
findings from stronger studies. However, the likely impact of each form of bias/ design 
limitation will be considered individually. 
Secondary objective 1: Investigating GMPs effect on compliance. One ‘mechanism’ through 
which GMP may improve control is through its widely-reported greater acceptability leading 
to improvements in compliance with the PKU diet in free-living subjects. This remains 
speculative however, and some studies suggesting GMP is preferable compare single 
servings of GMP and formula rather than complete formula-based and GMP-based diets, 
the latter of which contain fewer exchanges. A synthesis of study findings regarding 
compliance  levels with GMP diets (and any resulting impacts upon control) that considers 
the validity and reliability of methods used to monitor compliance may clarify matters.   
Assessing the strength of the evidence body reviewed for each age group, The strength of 
the entire evidence base (and thus the confidence that can be placed in the reviews 
findings) will be rated using GRADE (see final section). 
Item 16: Meta-bias 
The extent and likely impact of publication bias will be considered qualitatively, as funnel 
plots and statistical methods are inappropriate where heterogenity is pronounced, difficult 
to interpret and detect small study effects rather than publication bias perse. 
Item 17: Confidence in cumulative estimate. 
The quality of the entire body of evidence reviewed will be assessed using the GRADE 
system though adaptation was performed to permit its use in a narrative review. 
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